

ZOBAIR M. YOUNOSSI MD, MPH, FACP, FACG, AGAF
3300 Gallows Road
Falls Church, Virginia 22042
703-776-2540

PUBLICATIONS

Books

1. Z Younossi, J Ong, R O'Shea. *Contemporary Diagnosis and Management of Hepatitis C*. Handbooks in Health Care (First edition), 2003.
2. Z Younossi. *Practical Management of Liver Diseases*. (Textbook Editor), Cambridge Press, 1st edition, 2008.
3. M Jarrar, Z Younossi, A Baranova. Pathogenesis of Non Alcoholic Fatty Liver Disease and Circulatory Levels of Adipocytokines. VDM Verlag Publishing, Germany 2008

Journal Supplements

1. Z Younossi (Guest Editor). Viral Hepatitis: A Guide to Practicing Clinician. *Cleveland Clinic Journal of Medicine (Supplement)*;_October 2000.
2. Z Younossi (Guest Editor). Optimizing Adherence to Therapy in Chronic Hepatitis C: Challenges and Emerging Strategies. *Cleveland Clinic Journal of Medicine (Supplement)*, 3 (Vol. 71); 2004.
3. Z Younossi. Non-alcoholic Steatohepatitis and Non-alcoholic Fatty Liver Disease, *Clinics in Liver Disease (Guest Editor)*, 11(xiii-xiv); 2007
4. Z Younossi, J Capeau (Co-Editors). Metabolic Complications from Hepatitis C. *Liver International (Supplement)*: Volume 29, Supplement 2; 2009

Book Chapters

1. E Beutler, D Carson, J Sipe, J Romine, R McMillan, Z Younossi, V Rodgers, J Koziol. *Clinical Development of 2-Cholorodeoxyadenosine. Nucleosides in Cancer Therapy*. Beutler E (ed). Marcel Mekker. 1996.
2. Z Younossi. Acute Upper Gastrointestinal Bleeding. *Saunders Manual of Medical Practice*, 1st edition. 1999.
3. Z Younossi. Acute Upper Gastrointestinal Bleeding. *Saunders Manual of Medical Practice*, 2nd edition. 2000.
4. Z Younossi. Health-related Quality of Life Measurement in Patients with Chronic Liver Disease. *Advances in Hepatic Encephalopathy & Metabolism in Liver Disease*. Yurdaydin C, Bozkaya H (Editors). Ankara University Press. 2000.
5. S Herten, J Stoller, Z Younossi. Alpha-1 Antitrypsin Deficiency. (Book Chapter). *Hepatology: A Practical Approach* (First Edition). Elsevier Sciences. 2005.
6. G Grant, V Chandhoke, Z Younossi. Specific Disorders Associated with Non-Alcoholic Fatty Liver Disease. (Book Chapter). *Fatty Liver Diseases: Non-Alcoholic Steatohepatitis and Related Disorders*. Blackwell Publishers, 1st edition. 2004.
7. A Baranova, Z Younossi. Adipokines in Non-alcoholic Fatty Liver Diseases. *Adipose Tissue and Adipokines in Health and Disease* (First Edition). The Humana Press. 2006.
8. J Ong, Z Younossi. Epidemiology and Natural History of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis. *Clinics in Liver Disease* 2007;11(1):1-16.
9. P Mishra, N Rafiq, Z Younossi. Non-Alcoholic Fatty Liver Disease. *Practical Management of Liver Diseases*. (Younossi Z, Editor), Cambridge Press. 2008.
10. A Baranova, L Liotta, E Petricoin. New Technologies in the Study of Liver Diseases. *Clinician's Guide to Common Liver Diseases*. (Younossi Z, Editor), Cambridge Press. 2008.

11. A Dan, Z Younossi. Depressive Symptoms and Health-Related Quality Of Life. *Handbook of Disease Burdens and Quality of Life Measures*. (Victor Preedy and Ronald Ross Watson, Editors). Springer Press. 2008
12. A Baranova, A Biredinc, M Estep, ZM Younossi. Pathogenesis of obesity-related chronic liver diseases as the study case for the systems biology. *Textbook of Systems Biology for Signaling Networks* (Sangdun Choi, Editor). 2009
13. Z Younossi. Epidemiology and Clinical Presentation of Non Alcoholic Fatty Liver Disease. *Proceeding of 8th International Meeting on Therapy in Liver Disease 2010* (In Press).
14. J Kallman, Z Younossi. Quality of Life After Liver Transplantation for Hepatitis C. *Hepatitis C And Liver Transplantation Textbook* (Sandeep Mukherjee, MBBCh, Editor), 2010 (In press)
15. Nila Rafiq, and Zobair M. Younossi. Hepatic Changes of Obesity and the Effects of Weight Loss. *Handbook of Obesity Surgery*. Current Concepts and Therapy of Morbid Obesity and Related Diseases. Editors: Mervyn Deitel, Michel Gagner, John B. Dixon, Atul K. Madan, Jacques Himpens (In Press 2010)

Journal Articles

Articles Related to Non-Alcoholic Fatty Liver Disease and Obesity:

1. Z Younossi, T Gramlich, Y Liu, C Matteoni, M Pettrelli, J Goldblum, L Rybicki, AC McCullough. Non- Alcoholic Fatty Liver: Assessment of Variability in the Pathologic Interpretations. *Modern Pathology*, Vol. 11, (6):560-565; 1998.
2. Z Younossi. Non-Alcoholic Fatty Liver Disease: A Review. *Current Gastroenterology Reports*, Vol. 1 (No.1); 1999.
3. C Matteoni, Z Younossi, T Gramlich, N Boparai, Y Liu, A McCullough. A Non-Alcoholic Fatty Liver Disease: A Spectrum of Clinical and Pathologic Severity. *Gastroenterology*, 116-1413-1419; 1999.
4. S Saadeh, Z Younossi. Non-Alcoholic Fatty Liver Disease: A Spectrum from Steatosis to Non-Alcoholic Steatohepatitis. *Cleveland Clinic Journal of Medicine*, Vol. 67 (No.2):96-104; 2000.
5. J Ong, Z Younossi, V Reddy, T Gramlich, L Price, N Boparai. Cryptogenic Cirrhosis and Post-Transplant Non-Alcoholic Fatty Liver Disease. *Liver Transplantation*. Vol. 7 (No.9):797-801, 2001.
6. J Ong, Z Younossi, C Speer, N Boparai, T Gramlich. Chronic Hepatitis C and Superimposed Non-Alcoholic Fatty Liver Disease. *Liver*, 21:206-271, 2001.
7. S Saadeh, ZM Younossi, EM Remer, T Gramlich, JP Ong, M Hurley, KD Mullen, JN Cooper, MJ Sheridan. The Utility of Radiological Imaging in Non-Alcoholic Fatty Liver Disease. *Gastroenterology*, Vol. 123(No.3):745-50, 2002.
8. B Mulhall, J Ong, Z Younossi. Non-Alcoholic Fatty Liver Disease: An Overview. *Journal of Gastroenterology and Hepatology*, Vol. 17 (No.11):123-147, 2002.
9. ZM Younossi, AM Diehl, JP Ong. Non-Alcoholic Fatty Liver Disease: An Agenda for Clinical Research. *Hepatology*, Vol. 35(No.4):746-52, 2002.
10. J Ong, Z Younossi. Is Hepatocellular Carcinoma Part of the Natural History of Non-Alcoholic Steatohepatitis? *Gastroenterology*, Vol. 123(No.1):375-378, 2002.
11. J Ong, Z Younossi. Non-Alcoholic Fatty Liver Disease – Two Decades Later: Are We Smarter About Its Natural History? *American Journal of Gastroenterology*, Vol. 98(No. 9), 2003.
12. T Gramlich, D Kleiner, A McCullough, C Matteoni, N Boparai, Z Younossi. Pathologic Features Associated with Fibrosis in Non-Alcoholic Fatty Liver Disease. *Human Pathology*, Vol. 35 (No.2):196-199; 2004.
13. Z Younossi, T Gramlich, C Matteoni, N Boparai, A McCullough. Non-Alcoholic Fatty Liver Disease in Patients with Type II Diabetes. *Clinical Gastroenterology and Hepatology*, Vol. 2(No.3):262-265; 2004.

14. R Collantes, Z Younossi. Hepatitis C and Non-Alcoholic Fatty Liver Disease. *Hepatitis Index and Reviews*, Vol. II, No 1:5-6; 2004.
15. R Collantes, J Ong, Z Younossi. Non-Alcoholic Fatty Liver and the Epidemic of Obesity. *Cleveland Clinic Journal of Medicine*, Vol. 71(No.8):657-664; 2004.
16. B Mullhall, Z Younossi. Non-Alcoholic Steatohepatitis. *Current Treatment Options in Gastroenterology*, 7:423-430, 2004.
17. Z Younossi. Interactions Between Nonalcoholic Fatty Liver Disease and Hepatitis C Viral Infection. *Journal of Gastroenterology and Hepatology* 19, S253-S257; 2004.
18. T Taddei, Z Younossi. The Efficacy of Weight Reduction In Nonalcoholic Fatty Liver Disease. *Evidence-Based Gastroenterology*. 5(3):96-97, August 2004.
19. J Ong, H Elariny, R Collantes, A Younoszai, V Chandhoke, HD Reines, Z Goodman, ZM Younossi. Predictors of Nonalcoholic Steatohepatitis and Advanced Fibrosis in Obese Patients *Obesity Surgery* 15(3):310-15, 2005.
20. Z Younossi, F Gorreta, J Ong M, K Schlauch, L Del Giacco, H Elariny, A Younoszai, Z Goodman, A Christensen, V Chandhoke, G Grant. Hepatic Gene Expression in Patients with Non-alcoholic Steatohepatitis. *Liver Int.* 25(4):760-71, 2005.
21. A Baranova, R Collantes, SJ. Gowder, H Elariny, K Schlauch, A Younoszai, S King, M Randhawa, S Pusulury, T Alsheddi, JP. Ong, LM. Martin, V Chandhoke, ZM. Younossi, MD. Obesity-related Differential Gene Expression in the Visceral Adipose Tissue. *Obes Surg.* 15(6):758-65, 2005.
22. S Srivastava, Z Younossi. Morbid Obesity, Non-Alcoholic Fatty Liver Disease, and Weight Loss Surgery. *Hepatology* 42(2):490-92, 2005.
23. R Collantes, Z Younossi. Nonalcoholic Fatty Liver Disease and Diabetes. *Panminerva Medica*, 2005.
24. J Ong, Z Younossi. Approaches to the Diagnosis and Therapy of Non-alcoholic Fatty Liver Disease. *Clinics in Liver Disease*, 9(4):617-634, 2005.
25. A Baranova, K Schlauch, S Gowder, R Collantes, V Chandhoke, Z Younossi. Microarray Gene Expression Studies of Obesity-Related Non-Alcoholic Fatty Liver Disease. *Liver International*; 25 (6):1091-1096, 2005.
26. Z Younossi, A Baranova, K Ziegler, L Del Giacco, K Schlauch, T Born, H Elariny, F Gorreta, A VanMeter, A Younoszai, J Ong, Z Goodman, V Chandhoke. A Genomic and Proteomic of Study of the Spectrum of Non-Alcoholic Fatty Liver Disease. *Hepatology* 41(3):665-674. 2005.
27. RS Collantes, JP Ong, ZM Younossi. The Metabolic Syndrome and Nonalcoholic Fatty Liver Disease. *Panminerva Med.*, 48(1):41-8, 2006.
28. M Mendoza, Z Younossi. Diabetic Hepatosclerosis: A Novel Entity or a Rare Form of Non-Alcoholic Fatty Liver Disease. *Hepatology*, 44(5):1362-3, 2006.
29. A Baranova, R Collantes, K Schlauch, H Elariny, Z Younossi. A Comparison of Serum Levels and Gene Expression of Leptin, Resistin and Adiponectin in the Adipose Tissue of Obese Patients with Non-Alcoholic Fatty Liver Disease and Insulin Resistance. *Obesity Surgery*, 16(9):1118-25, 2006.
30. M Mendoza, Z Younossi. Diabetic Hepatosclerosis: A Novel Entity or a Rare Form of Non-Alcoholic Fatty Liver Disease. *Hepatology*, 44(5):1362-3, 2006.
31. A Baranova, R Collantes, K Schlauch, H Elariny, Z Younossi. A Comparison of Serum Levels and Gene Expression of Leptin, Resistin and Adiponectin in the Adipose Tissue of Obese Patients with Non-Alcoholic Fatty Liver Disease and Insulin Resistance. *Obesity Surgery*, 16(9):1118-25, 2006.
32. S Bondini, J Kallman, A Wheeler, S Prakash, T Gramlich, D Jondle, ZM. Younossi. The Impact of Non-Alcoholic Fatty Liver Disease on Chronic Hepatitis B. *Liver International*, 27(5):607-11, 2007
33. Z Younossi, A McCullough, J Ong, D Barnes, A Post, A Tavill, D Bringman, L Martin, J Assmann, T Gramlich, K Mullen, R O'Shea, W Carey, R Ferguson. Obesity and Non-Alcoholic Fatty Liver Disease in Chronic Hepatitis C. *Journal of Clinical Gastroenterology*, Vol. 38:705-709, 2004.
34. Z Younossi: Non-alcoholic Fatty Liver Disease: Detection & Treatment: *World Gastroenterology News*: Vol 12: 14-15, 2007.

35. A Baranova, M Randhawa, M Jarrar, ZM. Younossi. Adipokines and Melanocortins in the Hepatic Manifestation of Metabolic Syndrome: Non-Alcoholic Fatty Liver Disease. *Expert Review of Molecular Diagnostics* 7 (2): 195-205, 2007.
36. S Bondini, DE Kleiner, ZD Goodman, T Gramlich, ZM. Younossi. Pathologic Assessment of Non-alcoholic Fatty Liver Disease. *Clinics in Liver Disease* 11:17-23, 2007.
37. JP Ong, ZM Younossi. Epidemiology and Natural History of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis. *Clinics in Liver Disease* 11:1-16, 2007.
38. A Baranova, L Liotta, E Petricoin, ZM. Younossi, The Role of Genomics and Proteomics Technologies in Studying Non-Alcoholic Fatty Liver Disease. *Clinics in Liver Disease* 11:209-220, 2007.
39. ZM Younossi, Preface. Non-alcoholic Fatty Liver Diseases and Non-alcoholic Steatohepatitis. *Clinics in Liver Disease* 11 (2007) xxii-xiv.
40. P Mishra, ZM Younossi. Current Treatment Strategies for Non-alcoholic Fatty Liver Disease. *Current Drug Discovery Technologies*. 4:133-140, 2007
41. C Nugent, ZM Younossi. Evaluation and Management of Obesity-related Non-alcoholic Fatty Liver Disease. *Nature Clinical Practice Gastroenterology & Hepatology* 14 (No. 8):432-441, 2007.
42. VS Calvert, R Collantes, H Elariny, Arian Afendy, A Baranova, M Mendoza, Z Goodman, L Liotta, EF Petricoin, ZM. Younossi. A Systems Biology Approach to Non Alcoholic Fatty Liver Disease Pathogenesis Using Multiplexed Cell Signaling Analysis. *Hepatology* 46 (1):166-172, 2007
43. Z Younossi: Non-alcoholic Fatty Liver Disease: Detection & Treatment: *World Gastroenterology News*: Vol 12: 14-15, 2007.
44. A Baranova, M Randhawa, M Jarrar, ZM. Younossi. Adipokines and Melanocortins in the Hepatic Manifestation of Metabolic Syndrome: Non-Alcoholic Fatty Liver Disease. *Expert Review of Molecular Diagnostics* 7 (2): 195-205, 2007.
45. S Bondini, DE Kleiner, ZD Goodman, T Gramlich, ZM. Younossi. Pathologic Assessment of Non-alcoholic Fatty Liver Disease. *Clinics in Liver Disease* 11:17-23, 2007.
46. JP Ong, ZM Younossi. Epidemiology and Natural History of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis. *Clinics in Liver Disease* 11:1-16, 2007.
47. A Baranova, L Liotta, E Petricoin, ZM. Younossi. The Role of Genomics and Proteomics Technologies in Studying Non-Alcoholic Fatty Liver Disease. *Clinics in Liver Disease* 11:209-220, 2007.
48. ZM Younossi, Preface. *Clinics in Liver Disease* 11 (2007) xxii-xiv.
49. VS Calvert, R Collantes, H Elariny, Arian Afendy, A Baranova, M Mendoza, Z Goodman, L Liotta, EF Petricoin, ZM. Younossi. A Systems Biology Approach to Non Alcoholic Fatty Liver Disease Pathogenesis Using Multiplexed Cell Signaling Analysis. *Hepatology* 46 (1):166-172, 2007
50. C Nugent, ZM Younossi. Evaluation and Management of Obesity-related Non-alcoholic Fatty Liver Disease. *Nature Clinical Practice Gastroenterology & Hepatology* 14 (No. 8):432-441, 2007.
51. P Mishra, ZM Younossi. Current Treatment Strategies for Non-alcoholic Fatty Liver Disease. *Current Drug Discovery Technologies*. 4:133-140, 2007.
52. A Baranova, K Schlauch, H Elariny, M Jarrar, C Bennett, C Nugent, S Crowder, R Collantes, ZM Younossi Gene Expression Patterns in the Hepatic Tissue and in the Visceral Adipose Tissue of Patients with Non-Alcoholic Fatty Liver Disease. *Obesity Surgery*. 17(8):1111-8, 2007.
53. A Dan, J Kallman, A Wheeler, Z Younoszai, R Collantes, S Bondini, L Gerber, Z Younossi. Health-related Quality of Life in Patients with Non-Alcoholic Fatty Liver Disease. *Alimentary Pharmacology & Therapeutics* 26(6):815-820, 2007
54. P Mishra, ZM. Younossi. Abdominal Ultrasound for Diagnosis of Non-Alcoholic Fatty Liver Disease. *Am J of Gastro*. 102(12):2716-7, 2007
55. Petricoin, ZM Younossi. Reply to the letter to the Editor: Bioinformatics as a Tool to Identify Gene/Protein-Pathways Associated with Non-Alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis. *Hepatology* 46(4):1306-1307, 2007

56. A Baranova, Z Younossi. The Future Is Around the Corner: Non-Invasive Diagnosis of the Progressive Nonalcoholic Steatohepatitis. *Hepatology*. 2008; 47(2):373-5
57. M Jarrar, A Baranova, R Collantes, B Ranard, M Stepanova, C Bennett, Y Fang, H Elariny, Z Goodman, V. Chandhoke, ZM. Younossi. Adipokines and Cytokines in Non-Alcoholic Fatty Liver Disease. *Alimentary Pharmacology & Therapeutics* 2008; 1;27(5):412-21.
58. Z Younossi. Current Management of Non-alcoholic Fatty Liver Disease. *Aliment Pharmacol Ther*. 2008 Jul;28(1):2-12.
59. C Nugent, CH Bai, H Elariny, P Gopalakrishnan, C Quigley, M Garone Jr., M Afendy, O Chan, A Wheeler, A Afendy, ZM Younossi. Improvement of Metabolic Syndrome after Laparoscopic Bariatric Surgery. *Obes Surg*. 2008; 18(10):1278-86.
60. A Baranova, Z Younossi. Reply to the Letter to the Editor: "A "Biomarker Biopsy" for the Diagnosis of NASH: Promises from CK-18 Fragments" by Yusuf Yilmaz, Engin Ulukaya, Enver Dolar. *Obes Surg*. 2008; 18(11):1509-10.
61. Z Younossi, M Jarrar, C Nugent, M Afendy, C Quigley, M Stepanova, H Elariny, Z Goodman, V Chandhoke. A Novel Diagnostic Biomarker Panel for Obesity Related Non-Alcoholic Steatohepatitis. *Obesity Surg* 2008;18(11):1430-7.
62. CH Kim, ZM Younossi. Non-Alcoholic Fatty Liver Disease. *Cleveland Clinic J of Medicine* 2008; 75 (9):673-680
63. C H Kim, J Kallman, CH Bai, L Pawloski, C Gewa, A Arsalla, ME Sabatella, ZM. Younossi Nutritional Assessments of Patients with Non-Alcoholic Fatty Liver Disease. *Obesity Surgery* 2008 Jun 17. [Epub ahead of print]
64. JP. Ong, A Pitts, ZM. Younossi. Increased Mortality and Liver-Related Mortality in Patients with Nonalcoholic Fatty Liver Disease. *J of Hepatology* 2008; 49:608-612
65. P Mishra, C Nugent, A Afendy, C Bai, P Bhatia, M Afendy, Y Fang, H Elariny, Z Goodman, ZM. Younossi. Apneic-Hypopneic Episodes during Obstructive Sleep Apnea are Associated with Histologic Nonalcoholic Steatohepatitis (Non-alcoholic Steatohepatitis). *Liver International* 2008 28(8):1080-6.
66. W Dunn, R Xu, D Wingard, C Rogers, P Angulo, ZM Younossi, JB. Schwimmer, Suspected Nonalcoholic Fatty Liver Disease and Mortality Risk in a Population-based Cohort Study. *Am J of Gastroenterology* 2008; 103(9):2263-71
67. N Rafiq, Z Younossi. Weight Loss and Its Impact on Non-Alcoholic Fatty Liver Disease. *Seminars in Liver Disease* 2008; 28 (4):427-33
68. N Rafiq, ZM Younossi. Can we Use Clinical Parameters to Predict Non-Alcoholic Steatohepatitis in Morbidly Obese Patients? *Evidence-Based Gastroenterology* 2008; 9 (No 3):69-70
69. M Randhawa, T Huff, JC Valencia, ZM Younossi, V Chandhoke, VJ. Hearing, A Baranova. Evidence for the Ectopic Synthesis of Melanin in Human Adipose Tissue. *FASEB J*. 2009 Mar;23(3):835-43.
70. N Rafiq, CH Bai, Y Fang, M Srishord, A McCullough, T Gramlich, ZM Younossi. Long-Term Follow-Up of Patients with Non-Alcoholic Fatty Liver. *Clinical Gastro and Hepatology* 2009; 7(2):234-8
71. Z Younossi, A McCullough. Metabolic Syndrome, Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus: Impact on Disease Progression and Treatment Response. *Liver Int*. 2009 Mar; 29 Suppl 2:3-12.
72. B Lam, Z Younossi. Treatment of Non-Alcoholic Fatty Liver Disease. *Annals of Hepatology* 2009; 8 (1): Supplement: S51-S59
73. Kallman JB, Arsalla A, Park V, Dhungel S, Bhatia P, Haddad D, Wheeler A, Younossi ZM. Screening for Non-alcoholic Fatty Liver Disease (NAFLD), Hepatitis B (HBV) AND Hepatitis C (HCV): A Survey of Community-based Physicians. *Aliment Pharmacol Ther*. 2009 May 1;29(9):1019-24.
74. N Rafiq, Z Younossi. Evaluation and Management of Non-Alcoholic Fatty Liver Disease. *Clinics in Liver Disease* 2009; 13:249-266

75. JM Estep, A Baranova, N Hossain, H Elariny, K Ankrah, A Afendy, V Chandhoke, ZM. Younossi. Expression of Cytokine Signaling Genes in Non-Alcoholic Steatohepatitis and Hepatic Fibrosis. *Obes Surg.* 2009 May;19 (5):617-24.
76. N Hossain, A Afendy, M Stepanova, F Nader, M Srishord, Z Goodman, Z Younossi. Independent Predictors of Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease. *Clin Gastroenterol Hepatol.* Nov 2009;7(11):1224-9
77. ZM. Younossi, A Afendy, M Stepanova, N Hossain, I Younossi, K Ankrah, T Gramlich, A Baranova. Gene Expression Profile Associated with Superimposed Non-Alcoholic Fatty Liver Disease in Patients with Chronic Hepatitis C. *Liver Int.* 2009 Volume 29, Issue 9:1403-1412
78. J Ong, M Stepanova, ZM Younossi. Outcomes of patients with Non-Alcoholic Fatty Liver Disease. *J of Hepatology* 2009
79. JP Ong, ZM Younossi. Non-Alcoholic Fatty Liver Disease after Liver Transplantation: A Case of Nurture and Nature. *Am J of Gastroenterology* 2010, Vol 105, Issue 3:621-623
80. B Lam, ZM Younossi. Treatment options for Non-Alcoholic Fatty Liver Disease. *Therapeutic Advances in Gastroenterology* 2010 (In Press).
81. M Stepanova, N Houssain, A Afendy, ZD. Goodman, A Baranova, ZM Younossi. Hepatic Gene Expression of Caucasian and African-American Patients with Non-Alcoholic Fatty Liver Disease. *Obes Surg.* 2010 May; 20(5):640-50.
82. M Stepanova, R Aquino, A Alsheddi, R Gupta, Y Fang, ZM Younossi. Clinical Predictors of Fibrosis in Patients with Chronic Liver Disease. *Aliment Pharmacol Ther* 2010, ;31(10):1085-94
83. Z Younossi, A Baranova, M Stepanova, V Calvert, A Afendy, Z Goodman, L Liotta, E Petricoin. Phosphoproteomic Biomarkers Predicting Histologic Nonalcoholic Steatohepatitis and Fibrosis. *J Proteome Res. J Proteome Res.* 2010, 4;9(6):3218-24.
84. J Kallman, A Wheeler, HK Alathari, Y Fang, M Stepanova, H Elrainy, ZM Younossi. Association of Components of Metabolic Syndrome with Depression and Anxiety in Patients Undergoing Weight Reduction Surgery. *Open Obesity Journal* 2010, 2:125-131
85. M Estep, D Armistead, N Hossain, H Elarainy, Z Goodman, A Baranova, ZM Younossi. Differential Expression of miRNAs in the Visceral Adipose of Patients with Non-Alcoholic Fatty Liver Disease. *Aliment Pharmacol Ther* 2010;32(3):487-97.
86. Rohini Mehta, Aybike Birerdinc, Noreen Hossain, Arian Afendy, Vikas Chandhoke, Zobair Younossi, Ancha Baranova. Validation of endogenous reference genes for qRT-PCR analysis of human visceral adipose samples. *BMC Molecular Biology* 2010, 11:39.
87. ZM. Younossi, S Page, N Rafiq, A Birerdinc, M Stepanova, N Hossain, A Afendy, Z Younoszai, Z Goodman, A Baranova. A Biomarker Panel for Non-alcoholic Steatohepatitis (NASH) and NASH-Related Fibrosis. *Obesity Surgery* 2010 (In Press)
88. M Stepanova, N Rafiq, ZM. Younossi. Components of Metabolic Syndrome as Independent Predictors of Mortality In Chronic Liver Disease: A Population-Based Study. *Gut* (In Press) 2010.
89. N Hossain, M Stepanova, A Afendy, F Nader, N Rafiq, Z Goodman, ZM. Younossi. Non-Alcoholic Steatohepatitis (NASH) in Patients with Polycystic Ovarian Syndrome (Submitted 2010)

Articles Related to Quality of Life Research:

90. Z Younossi. Quality of Life Assessment and Chronic Liver Disease. *American Journal of Gastroenterology*, Vol. 93 (7):1037-1041; 1998.
91. Z Younossi. Economic and Quality of Life Outcomes in Viral Hepatitis. *Viral Hepatitis Reviews*, Vol. 5 (No. 6):220-230, 1999.
92. Z Younossi, G Guyatt, M Kiwi, D King, N Boparai. Development of a Disease-Specific Health-Related Quality of Life Index for Chronic Liver Disease. *Gut*, 44:1-6; 1999.
93. Z Younossi, M Kiwi, N. Boparai, G Guyatt. An In-Depth Assessment of Quality of Life in Chronic Cholestatic Liver Disorders. *American Journal of Gastroenterology*, Vol. 95 (No.2):497-502; 2000.

94. Z Younossi, M McCormick, N Boparai, L Farquhar, JM Henderson, G Guyatt. The Impact of Liver Transplantation on Health-Related Quality of Life. *Liver Transplantation*, Vol. 6:779-783; 2000.
95. Z Younossi, N Boparai, M McCormick, G Guyatt. Assessment of Utilities and Health-Related Quality of Life in Chronic Liver Diseases. *American Journal of Gastroenterology*, Vol. 96 (No.2): 579-583; 2001.
96. Z Younossi, N Boparai, M Kiwi, L Price, M Kiwi, G Guyatt. Health-Related Quality of Life Assessment in Chronic Liver Disease: Impact of Type and Severity of Disease. *American Journal of Gastroenterology*, Vol. 96 (No.7):2199-2205, 2001.
97. Z Younossi, N Boparai, M McCormick, L Price, G Guyatt. Assessment of Utilities and Health-Related Quality of Life in Patients with Chronic Liver Disease. *American Journal of Gastroenterology*, Vol. 96, (No.2):579-583, 2001.
98. LM Martin, MJ Sheridan, ZM Younossi. The Impact of Liver Disease on Health-Related Quality of Life: A Review of the Literature. *Current Gastroenterology Reports*, Vol. 4(No.1):79-83, 2002.
99. L Martin, K Irwin, Z Younossi. Health-Related Quality of Life and Chronic Liver Disease: Conceptual Challenges and Clinical Applications. *Clinical Perspective in Gastro*, 60-63, 2002.
100. P Pockros, M Shiffman, E Schiff, M. Sulkowski, ZM Younossi, DT. Dieterich, T Wright, SH. Mody, K Tang, BL. Goon, PJ. Bowers, G Leitz, N Afdhal and the PROACTIVE Study Group. Epoetin Alfa Improves Quality of Life in Anemic HCV-infected Patients Receiving Combination Therapy. *Hepatology* 40(6):1450-8, 2004.
101. S Saab, A Ibrahim, A Shpaner, Z Younossi, C Lee, F Durazo, S Han, K Esrason, V Wu, D Farmer, M Ghobrial, C Holt, Pharm, H Yersiz, L Goldstein, M Tong M, R Busuttil. MELD Fails to Measure Quality of Life in Liver Transplant Candidates. *Liver Transplantation&Surgery* 11(2):218-23, 2005.
102. B Spiegel, ZM. Younossi, RD Hayes, D Revicki, S Robbins, F Kanwal. The Impact of Hepatitis C on Health Related Quality of Life: A Systematic Review and Quantitative Assessment. *Hepatology*; 41 (4):790-800, 2005.
103. L Martin, Z Younossi. Health-Related Quality of Life (HRQL) in Chronic Liver Disease. *Digestive and Liver Disease* 37 (11):819-820, 2005.
104. L Martin, A Dunn, Z Younossi. Measurement of Health-Related Quality of Life in Patients with Chronic Liver Disease. *Liver Transplantation* 12 (1):22-23, 2006.
105. A Dunn, L Martin, D Farmer, C Crone, J Ong, T Wise, S Robbins, ZM. Younossi. Depression, anemia and health-related quality of life in chronic hepatitis C. *J Hepatology*, 27:122-129, 2006
106. Z Younossi, J Kallman, J Kincaid. The Effects of HCV Infection and Management on Health-Related Quality of Life. *Hepatology* 45 (3): 806-816, 2007
107. J Kallman, MM O'Neill, B Larive, N Boparai, L Calabrese, ZM. Younossi. Fatigue and Health-related Quality of Life (HRQL) in Chronic Hepatitis C Virus Infection. *Dig Dis and Sciences*. 52(10):2531-9, 2007.
108. A Dan, L Martin, C Crone, J Ong, T Wise, L Ramsey, MS Sjogren ZM. Younossi. Anger Experiences among Hepatitis-C Patients: Relationship to Depressive Symptoms and Health-Related Quality of Life. *Psychosomatics*. 48(3):223-9, 2007.
109. B Spiegel, R Bolus, S Han, M Tong, E Esrailian, J Talley, T Tran, J Smith, J Karsan, F Durazo, B Bacon, P Martin, Z Younossi, S Hwa-Ong, F Kanwal. Development and Validation of a Disease-Targeted Health-Related Quality Of Life Instrument In Chronic Hepatitis B Infection: The HBQOL.1 V1.0. *Hepatology*, 46 (1):113-121 2007
110. S Bondini, J Kallman, A Dan, Z Younoszai, L Ramsey, F Nader, ZM. Younossi Health-Related Quality Of Life in Patients With Chronic Hepatitis B. *Liver International*. 27 (8):1119-1125, 2007
111. A Dan, J Kallman, R Srivastava, Z Younoszai, A Kim, Z Younossi. Health Utilizing assessment using SF-6D as Health Utility Index in patient with Chronic Liver Disease. *Liver Transplantation* 2008; 14(3):321-6.
112. KH Schulz, S Kroencke, H Ewers, H Schulz, ZM Younossi. The Factorial Structure of the Chronic Liver Disease Questionnaire (CLDQ). *Qual Life Res*. 2008 Apr 4; [Epub ahead of print]

113. R Two, A Verjee-Lorenz, D Clayson, M Dalal, ZM Younossi. A Methodology for Successfully Producing Global Translations of Patient-Reported Outcome Measures for Use in Multiple Countries. *Value Health*. 2009 Aug 20. [Epub ahead of print]
114. A Afendy, J Kallman, M Stepanova, Z Younoszai, R Aquino, G Bianchi, G Marchesini, ZM Younossi. Predictors of Health-Related Quality Of Life (HRQL) In Patients with Chronic Liver Disease. *Aliment Pharmacol Ther* 2009;30(5):469-76
115. JP Ong, C Krüger-Jansen, G Oehler, J Lambert-Baumann, ZM. Younossi. The Impact of Oral L-Ornithine-L-Aspartate For The Treatment Of Hepatic Encephalopathy On Health-Related Quality Of Life. Submitted 2009

Articles Related to Outcomes and Health Services Research:

116. Z Younossi, G Guyatt. Evidence-Based Medicine: A Method for Solving Clinical Problems in Hepatology. *Hepatology*, Vol. 30 (No. 4);829-832; 1999.
117. A Aggarwal, J Ong, Z Younossi, D Nelson, J Schafle, L Hoffman Hogg, A Arroliga. Predicators of Morality and Resource Utilization for Patients with Chronic Liver Disease Admitted to the Medical Intensive Care Unit. *Chest*, 119:1489-1493, 2001.
118. A Aggarwal, JP Ong, M Goormastic, DR Nelson, AC Arroliga, L Farquhar, J Mayes, ZM Younossi. Survival and Resource Utilization in Liver Transplant Recipients: The Impact of Admission to the Intensive Care Unit. *Transplant Proc.*, Vol. 35(No.8): 2998-3002, 2003.
119. T Gildea, WC Cook, DR Nelson, A Aggarwal, W Carey, ZM Younossi, AC Arroliga. Predictors of Long-term Mortality in Patients With Cirrhosis of the Liver Admitted to a Medical ICU. *Chest* 126(5):1598-603; 2004.
120. J Ong, R Collantes, A Pitts, L Martin, M Sheridan, Z Younossi. High Rates of Uninsured among Hepatitis C Positive Patients. *Journal of Clinical Gastroenterology* 39(9):826-830. 2005
121. A Dunn, ZM. Younossi Outcome and Quality of Life in Patients with Polycystic Liver Disease after Liver or Combined Liver-Kidney Transplantation. *Liver Transplantation*, 12(8):1184-5, 2006.
122. CH Kim, ZM. Younossi. New Agents for Treatment of Chronic Hepatitis B: Are they Cost-Effective? *Evidence-Based Gastroenterology*. 8(1):25-26, February 2007.

Articles Related to Hepatitis C:

123. Z Younossi, J McHutchison. Serologic Tests for HCV Infection. *Viral Hepatitis Reviews*, Vol.2, (No.3): 161- 173; 1996.
124. Z Younossi. Hepatitis C: A Clinical Overview. *Cleveland Clinic Journal of Medicine*, Vol. 64:259-268; 1997.
125. K Sheathe, Z Younossi. Diagnostic Assays for Viral Hepatitis B and C. *Practical Gastroenterology*, Vol. XXII (5):39- 48; 1998.
126. Z Younossi, P Canuto. Hepatitis C update: Implication of Blood Transfusion Look Back. *Cleveland Clinic Journal of Medicine*, Vol. 65 (No. 8), 1998.
127. Z Younossi, P Canuto. Hepatitis C Update: Implication of Blood Transfusion Look back. *The Cleveland Clinic Journal of Medicine*, Vol. 65(No.8); 1998.
128. Z Younossi, W Braun, D Protiva, R Gifford, R Straffon. Chronic Viral Hepatitis in Renal Transplant Recipients with Allografts Functioning for More than Twenty Years. *Transplantation*, Vol. 67 (2):272-275; 1999.
129. C Matteoni, Z Younossi. Hepatitis C Testing: What Test for Which Patient. *Cleveland Clinic Journal of Medicine*, Vol. 66 (No.9):529- 530; 1999.
130. Z Younossi, T Gramlich, N Boparai, P George, J Mayes. Concordance in Pathologic Interpretation of Liver Biopsies in Post-Transplant Hepatitis C: Recurrence vs. Acute Cellular Rejection. *Archive of Pathology and Lab Medicine*, Vol. 123:143-145; 1999.

131. J Ong, D Barnes, Z Younossi, M Goormastic, T Gramlich, B Yen-Lieberman, K Hoersher, C Sheffield, J Young, R Starling, N Smedria, P MacCarthy. Outcomes of DeNovo Hepatitis C Virus Infection in Heart Transplant Recipients. *Hepatology*, Vol. 30 (No.5):1293-1298; 1999.
132. Z Younossi, M Singer, J McHutchison, K Shermock. Cost-Effectiveness of Interferon-Alpha 2b Combined with Ribavirin for the Treatment of Chronic Hepatitis C. *Hepatology*, Vol. 30 (No. 5):1328-1334; 1999.
133. Z Younossi, R Perillo. The Roles of Amantadine, Rimantadine, Ursodeoxycholic Acid and NSAIDS, Alone or in Combination with Alpha Interferon's in the Treatment of Chronic Hepatitis C. *Seminars in Liver Disease (Supplement)*, Vol. 19, 1:95-102; 1999.
134. D Zdilar, K Franco-Bronson, N Buchler, J Locala, Z Younossi. Hepatitis C, Interferon-Alpha and Depression. *Hepatology*. Vol. 31 (No.6): 1207-1211; 2000.
135. S Sarbah, Z Younossi. Hepatitis C: An Update on the Silent Epidemic. *Journal of Clinical Gastroenterology*, Vol. 30:125-143, 2000.
136. Z Younossi. Viral Hepatitis Guide to Practicing Physicians. *Cleveland Clinic Journal of Medicine*, 67, Supplement 1:SI6-45, 2000.
137. J McHutchison, Z Younossi. Treatment Strategies for Hepatitis C: Making the Best of Limited Options. *Cleveland Clinic Journal of Medicine*; 67:1-5, 2000.
138. Z Younossi. Chronic Hepatitis C in Young Healthy Individuals. *Evidence-Based Gastroenterology*, 1, 1:34-35, 2000.
139. J McHutchison, Z Younossi. Do Nonsteroidal Anti-Inflammatory Agents Improve Response to Interferon in Patients with Chronic Hepatitis C Virus Infection? *Evidence-Based Gastroenterology*,1:38-39, 2000.
140. S Saadeh, G Cammell, K Easley, Z Younossi, W Carey. Role of Liver Biopsy In Chronic Hepatitis C. *Hepatology*, Vol. 33(No.1):196-200; 2001.
141. J Ong, Z Younossi, T Gramlich, Z Goodman, J Mayes, S Sarbah, B Yen-Lieberman. Interferon alpha 2b And Ribavirin in Severe Recurrent Cholestatic HCV. *Transplantation*; 71 (10):1486-1488, 2001.
141. Z Younossi, K Mullen, W Zakko, S Hodnick, E Brandt, D Barnes, W Carey, A McCullough, K Easley. A Randomized, Double-Blind Controlled Trial of Interferon Alpha-2b and Ribavirin vs. Interferon Alpha-2b and Amantadine for Treatment of Chronic Hepatitis C, Non-Responders to Interferon. *Journal of Hepatology*, 34:128-133; 2001.
142. E Hadziyannis, A Hadziyannis, S Savas, I Rapti, M Kiwi, S Hodnick, F Spanou, C Starkey, B Yen-Liebeunan, Z Younossi. Hepatitis C Virus RNA Assays: Comparison of Superquant and Monitor . *Journal of Clinical Gastroenterology*, Vol. 33 (No.1):45-48, 2001.
143. M Singer, Z Younossi. Cost-Effectiveness of Screening for Hepatitis C Virus in Asymptomatic, Average Risk Adults: Has the Time Come? *American Journal of Medicine*, 111:614-621, 2001.
144. KM Shermock, ME Temple, Z Younossi. A Pharmacoeconomic Appraisal of Therapies for Hepatitis B and C. *Expert Opinion on Pharmacotherapy*, Vol. 2(No.2):205-211, 2001.
145. KM Shermock, ME Temple, Z Younossi. The Cost-Effectiveness of Treating Chronic Hepatitis C. *Drug Benefit Trends*, 14 (A):34-40, 2002.
146. K Shariieff, D Duncan D, Z Younossi. Advances in Treatment of Chronic Hepatitis C: Pegylated Interferons. *Cleveland Clinic Journal of Medicine*, Vol. 69(No.2):155-9, 2002.
147. B Mulhall, Z Younossi. Can Anti-Viral Therapy Improve Hepatitis C Related Fibrosis? *Evidence-Based Gastroenterology*, Vol. 3(No 2):67-68, 2002.
148. T Poynard, V Ratziu, J McHutchison, M Manns, Z Goodman, S Zeuzem, Z Younossi, J Albrecht. Effect of Treatment with Peginterferon or Interferon Alfa-2b and Ribavirin on Steatosis in Patients Infected with Hepatitis C. *Hepatology*, Vol. 38(No.1):75-85; 2003.
149. R Collantes, Z Younossi. Interferon Alfa-2b and Ribavirin Combination Is Effective In Patients with Hemophilia and Chronic Hepatitis C. *Evidence-Based Gastroenterology*. 4(1):26-28, February 2003.
150. M Duncan, Z. Younossi. Treatment Options for Nonresponders and Relapsers to Initial Therapy for Hepatitis C. *Cleveland Clinic Journal of Medicine*, 70 Supplement 4:S21-6, 2003.

151. Z Younossi, K Mullen, S Hodnick, D Barnes, W Carey, A McCullough, K Easley, T Gramlich, B Liebermann. Triple Combination of Interferon Alpha-2b, Ribavirin, and Amantadine for Treatment of Chronic Hepatitis C. *Journal Clinical Gastroenterology*, Vol. 36(No.5): 427-430; 2003.
152. A Di Bisceglie, A Lyra, M Schwartz, R Reddy, P Martin, G Gorges, A Lok, K Hussain, R Gish, D Van Thiel, Z Younossi et al. Hepatitis C-Related Hepatocellular Carcinoma: Influence of Ethnic Status. *American Journal of Gastroenterology*, Vol. 98 (No. 9): 2060-2063, 2003.
153. D Vassilopoulos, ZM Younossi, E Hadziyannis, N Boparai, B Yen-Lieberman, E Hsi, A Villa-Forte, E Ball, RP Kimberly, LH Calabrese. Study of Host and Virological Factors of Patients with Chronic HCV Infection and Associated Laboratory or Clinical Autoimmune Manifestations. *Clin Exp Rheumatol*. 21(6 Supplement 32):S101-11; 2003.
154. R Collantes, Z Younossi. Who is at Risk for Hepatitis C? *Cleveland Clinic Journal of Medicine*. Vol.71 (No.2):160-161; 2004.
155. J Ong, Z Younossi. Management of Anemia, Neutropenia, and Thrombocytopenia Associated with Antiviral Therapy for Chronic Hepatitis C. *Cleveland Clinic Journal of Medicine*, Supplement 3, Vol. 71:S17-S21; 2004.
156. J. Koff, Z Younossi. Hepatitis C with Normal Liver Enzymes: To Treat or Not to Treat. *American Journal of Gastroenterology*, Vol.9:6;972, 2004.
157. Z Younossi . Effective Hematologic Side Effect Management in Treatment of Chronic Hepatitis C. *Clinician's Companion VII*, 2004.
158. R Collantes, Z Younossi. Who is at Risk for Hepatitis C? *Cleveland Clinic Journal of Medicine*. Vol.71 (No.2):160-161; 2004.
159. J Ong, Z Younossi. Management of Anemia, Neutropenia, and Thrombocytopenia Associated with Antiviral Therapy for Chronic Hepatitis C. *Cleveland Clinic Journal of Medicine*, Supplement 3, Vol. 71:S17-S21; 2004.
160. NH Afdhal , DT Dieterich, PJ Pockros, ER Schiff, ML Shiffman, MS Sulkowski, T Wright T, ZM Younossi, BL Goon, KL Tang KL, PJ Bowers; Proactive Study Group. Epoetin Alfa Maintains Ribavirin Dose in HCV-Infected Patients: A Prospective, Double-Blind, Randomized Controlled Study. *Gastroenterology*, Vol.126; 5:1302-11, 2004.
161. J. Koff, Z Younossi. Hepatitis C with Normal Liver Enzymes: To Treat or Not to Treat. *American Journal of Gastroenterology*, Vol.9:6;972, 2004.
162. Z Younossi . Effective Hematologic Side Effect Management in Treatment of Chronic Hepatitis C. *Clinician's Companion VII*, 2004.
163. M Gupta, Z Younossi, Does Peginterferon Alfa-2a Have an Impact On Hepatitis C Recurrence After Orthotopic Liver Transplantation? *Evidence-Based Gastroenterology*. 6(2):61-62, May 2005.
164. B Mullhall, Z Younossi. The Impact of Adherence on Outcome of Antiviral Therapy of Chronic Hepatitis C. *Journal of Clinical Gastroenterology* 39:S23-S27, 2005.
165. B Spiegel, K Chen, M Broder, C Chiou, Z Younossi. Darbepoetin Alfa for the Management of Treatment-Induced Anemia in Hepatitis C: Clinical and Economic Consequences. *Clinical Gastroenterology and Hepatology* 3(10):1034-1042, 2005.
166. M Gupta, Z Younossi, Does Peginterferon Alfa-2a Have an Impact On Hepatitis C Recurrence After Orthotopic Liver Transplantation? *Evidence-Based Gastroenterology*. 6(2):61-62, May 2005.
167. B Mullhall, Z Younossi. The Impact of Adherence on Outcome of Antiviral Therapy of Chronic Hepatitis C. *Journal of Clinical Gastroenterology* 39:S23-S27, 2005.
168. R Collantes, Z Younossi. Management of Hematologic Side Effects of Peginterferon and Ribavirin with Growth Factors. *Journal of Clinical Gastroenterology* 39(1):S9-S13, 2005.
169. Z Younossi, A McCullough, D Barnes, A Post, J Ong , R O'Shea, L Martin, D Bringman, G Lavinthal, K Mullen, W Carey, T Tavill, R Ferguson, T Gramlich. Addition of Amantadine To Pegylated Interferon Alpha-2B And Ribavirin Does Not Improve The Efficacy of Anti-Viral Therapy For Chronic Hepatitis C. *Dig Dis Sciences* 50 (5):970-5, 2005
170. C Entwisle, ZM Younossi. How Often Should Patients With Hepatitis C Be Screened For Esophageal Varices? *Cleve Clin J Med*. ;73(8):758-9, 2006.

171. TD Schiano, M Charlton, Z Younossi, E Galun, T Pruett, R Tur-Kaspa, R Eren, S Dagan, N Graham, PV Williams, J Andrews. Monoclonal Antibody HCV-Abxt168 In Patients Undergoing Liver Transplantation For HCV: Results Of A Phase 2 Randomized Study. *Liver Transplantation*, 12(9):1381-9, 2006.
172. ZM Younossi. Specifically Targeted Antiviral Therapy (STAT-C) for Patients with Chronic Hepatitis C. *Medscape Gastroenterology*. P1-5. June 1, 2007.
173. N Rafiq, Z Younossi. The Impact of Steatosis on Viral Hepatitis B and C. *Practical Gastroenterology* 2007; XXXII (No.7):14-28
174. CH Kim, ZM. Younossi. Short Duration of Treatment for HCV Genotype 2 or 3 May Diminish Sustained Virologic Response. *Evidence Based Gastroenterology* 2007, Volume 8, Issue 4:75-77
175. H Gujral, ZM Younossi. Patients with Chronic Hepatitis C and No Health Insurance Coverage. *Cleveland Clinic Foundation CME Page*, 2007
176. Z Younossi, F Nader, C Bai, R Sjogren, JP. Ong, R Collantes, M Sjogren, L Ramsey, K Terra, H Gujral, C Gurung, M Srishord, Y Fang. A Phase II Dose Finding Study of Darbepoetin Alfa and Filgrastim in the Management of Anemia and Neutropenia in Chronic Hepatitis C. *J Viral Hepatitis*. 2008; 15(5):370-8.
177. ZM Younossi. New Directions in Hepatitis C Therapy: A Look at the Evolving Therapeutic Arsenal. *Medscape Gastroenterology* 2008 *Medscape Gastroenterology*. 2008, Posted 09/05/2008
178. I Bornman, ZM Younossi. Can the Dose of Ribavirin Be Reduced For Patients Infected With Hepatitis C, Genotypes 2 and 3? *Evidence-Based Gastroenterology* 2008; 9 (No 3):71-72
179. G Oeler, C Kruger-Jansen, ZM Younossi, Lambert-Baumann. L-Ornithin-L-Aspartat Verbessert Die Lebensqualität Von Patienten Mit Hepatischer Enzephalopathie. *Med Welt* 2008, 59:172-178.
180. H Mir, Z Younossi. Monoclonal and Polyclonal Antibodies to the HCV Envelope Protein. *Clinics in Liver Disease* 2009 Aug;13(3):477-86
181. A Birerdinc, A Afendy, M Stepanova, I Younossi, G Manyam, A Baranova, ZM. Younossi. Functional Pathway Analysis of Genes Associated with Response to Treatment for Chronic Hepatitis C. *J Viral Hepat*. 2010; 17:730-736.
182. Z Younossi. Mechanisms of Viral Eradication and Early Treatment in Hepatitis C: Implications for Therapy Clinical Update. *AGA/Medscape Clinical Update*; Published December 2009.
183. ZM. Younossi, A Baranova, A Afendy, R Collantes, A Bakshi, M Stepanova, G Manyam, C Santini, C Sigua, J Chan, A Iverson, SY Chang. Gene Expression Biomarkers Predicting Sustained Virologic Response in Patients with Chronic Hepatitis C Treated with Pegylated Interferon Alfa and Ribavirin. *Hepatology*. 2009 Mar; 49(3):763-74.
184. J Capeau, S Gharakhanian, Z Younossi. Metabolic Abnormalities in Chronic Hepatitis C. Introduction. *Liver Int*. 2009 Mar; 29 Suppl 2:1-2.
185. J Kallman, S Tran, A Arsalla, D Haddad, M Stepanova, Y Fang, VJ. Wrobel, M Srishord, ZM. Younossi. Vietnamese Community Screening for Hepatitis B (HBV) and Hepatitis C. *J Viral Hepat*. 2010 Feb 25. [Epub ahead of print]
186. ZM Younossi, M Stepanova. Hepatitis C Virus Infection, Age, and Hispanic Ethnicity Increase Mortality from Liver Cancer in the United States. *Clin Gastroenterol Hepatol*. 2010;8(8):718-23
187. A Baranova, M H. Jarrar, M Stepanova, A Johnson, N Rafiq, T Gramlich, V. Chandhoke, ZM. Younossi. Association of Serum Adipocytokines with Hepatic Steatosis and Fibrosis in Patients with Chronic Hepatitis C. *Digestion* 2010 (Accepted. In Press)
188. A Birerdinc, Z Younossi. Emerging Therapies for Hepatitis C. *Expert Opinion On Emerging Drugs* 2010 (Accepted. In Press)
189. M Estep, Z Younossi. Hepatitis C and Metabolic Syndrome. *Expert Review of Endocrinology and Metabolism* 2010 (In Press)
190. I Jacobson, P Cacoub, L Dal Maso, S Harrison, ZM Younossi. Chronic HCV infection II: Manifestations beyond the Liver. *Gastroenterology and Hepatology* 2010 (Accepted. In Press)

191. J Moon, J Kallman, P Winter, M Srishord, Y Fang, L Pawloski, L Gerber, ZM Younossi. Nutritional and Activity Level Disparities Between Patients with Hepatitis C and Healthy Blood Donors (Submitted 2010)

Articles Related to Other Liver Diseases:

192. L Miller, M Kalnoski, Z Younossi, J Bulinski, E Reisler. Antibodies Directed Against N Terminal Residues on Actin Do Not Block Acto-Myosin Binding. *Biochemistry*. 1985.
193. Z Younossi, P Foroozan. Crigler-Najjar Type II Treatment with Small-Dose Phenobarbital. *Digestive Diseases and Sciences*, Vol. 40, No. 3:575, 1995.
194. Z Younossi, P Pockros. Porphyria Cutanea Tarda and B-Immunoblastic Lymphoma: A case report. *American Journal of Hematology*, Vol. 51 (No.3):252, 1996.
195. Z Younossi, J McHutchison, T Ganiates. An Economic Analysis of Norfloxacin Prophylaxis against Spontaneous Bacterial Peritonitis. *Journal of Hepatology*, 27:295-298; 1997.
196. Z Younossi, W Strum, D Cloutier, P Teirstein, R Shatz. The Effect of Combined Anticoagulation and Low- Dose Aspirin on Upper Gastrointestinal Bleeding. *Digestive Diseases and Sciences*, Vol. 41, No.2; 1997.
197. Z Younossi, C Terran, T Ganiates, WD Carey. Ultrasound-Guided Liver Biopsy for Parenchymal Liver Disease: An Economic Analysis. *Digestive Diseases and Sciences*, Vol. 43 (3):46-50; 1998.
198. Z. Younossi, JG McHutchison, A Sedghi-Vaziri, CN Broussard. Transjugular Intrahepatic Porto-systemic Shunt and Changes in the Serum-Ascites Albumin Gradient. *Clinical Journal of Gastroenterology*, 27 (2):149-151; 1998.
199. J Ong, Z Younossi. Selective Bowel Decontamination and Its Use in Patients with Liver Disease: A Review. *Disease Management and Health Outcomes*, Vol. 4 (No.1): 17-26; 1998.
200. Z Younossi. Evaluating the Asymptomatic Individual Who has Mildly Elevated Liver Enzymes. *The Cleveland Clinic Journal of Medicine*, Vol. 65 (3):150-158; 1998.
201. Z Younossi. Epidemiology of Alcoholic Liver Disease. *Clinics of Liver Disease*, Vol. 2 (No.4):661-671; 1998.
202. B Parker, S Bhatia, Z Younossi, JM Henderson, J Tetzlaff. Autonomic Dysfunction of End-Stage Liver Disease Manifested as Defecation Syncope: Impact of Orthotopic Liver Transplantation. *Liver Transplantation and Surgery*, Vol. 5 (No. 6):497-501; 1999.
203. J Dumot, D Barnes, Z Younossi, J Henderson, W Carey. Immunogenicity of Hepatitis A Vaccine in Decompensated Liver Disease. *American J of Gastroenterology*, Vol. 94 (No.6):1601-1604; 1999.
204. J Ong, Z Younossi. Clinical Predictors of Large Esophageal Varices: How Accurate Are They: (Editorial) *American Journal of Gastroenterology*, Vol. 94 (No.11):3103-3105; 1999.
205. M Haug, M Ishitani, S Wimberley, W Carey, D Barnes, Z Younossi, J Mayes, M Henderson D Vogt. Hepatitis B immune globulin (HBIG) disposition after liver transplant (LT) in chronic hepatitis B (HBV). *Clinical Pharmacology and Therapeutics*. Volume 65, Issue 2, 1999, Page 128
206. A Duchini, Z Younossi, A Saven, G Bordin, H Knowles, P Pockros. An Open-Label Pilot Trial of Cladribine (2-CdA) in Patients with Primary Sclerosing Cholangitis. *Journal of Clinical Gastroenterology*, Vol. 31(No.4):292-296, 2000.
205. J Ong, M Sands, Z Younossi. Transjugular Intrahepatic Portosystemic Shunt: The Next Decade, *Journal of Clinical Gastroenterology*, Vol. 30: 14-28, 2000.
206. N Monserrate, JM Henderson, Z Younossi. Transjugular Intrahepatic Portosystemic Shunting and Ascites. *Evidence-Based Gastroenterology*, Vol. 1, (No.2) :78-79, 2000.
207. C Broussard, A Aggarwall, S Lacey, T Post, T Gramlich, M Henderson, Z Younossi. A Taste to Die for: Mushroom Poisoning- From Diarrhea to Liver Transplantation. *American Journal of Gastroenterology*, Vol. 96 (No.11):3195-3198, 2001.
208. BM Parker, SA Irefin, V Sabharwal, JE Tetzlaff, C Beven, Z Younossi, MT Karafa, DP Vogt, JM Henderson. Leukocyte Reduction during Orthotopic Liver Transplantation and Postoperative Outcome: A Pilot Study. *Journal of Clin Anesth.*, 16:18-24; 2004.

209. S Srivastava, Z Younossi Can Lamivudine Prevent The Progression Of Liver Disease In Chronic Hepatitis B? Evidence-Based Gastroenterology. 6(1):26-27, March 2005.
210. S Elgawly, ZM. Younossi, Transjugular Intrahepatic Portosystemic (TIPS) Improves Transplant-Free Survival In Cirrhotic Patients With Refractory Ascites. Evidence Based Gastroenterology 2008; Volume 9, Issue 1:9-11
211. G Aragon, Z Younossi, Telbivudine: Another Option for Treatment of Patients with Chronic Hepatitis B. Evidence Based Gastroenterology 2008; Volume 9, Issue 2:19-22
212. G Aragon, Z Younossi. Evaluation of Asymptomatic Elevation of Liver Enzymes. Cleve Clin J Med. 2010 Mar;77(3):195-204.
213. M Estep, A Bireddi, ZM Younossi. Biomarkers, the Pillars of Molecular Diagnostics and Personalized Medicine Revolution. Current Molecular Medicine 2009 (In Press)
214. JM Estep, G Grant, L O'Reilly, J Piper, J Jonsson, J Assmann, V Chandhoke, Z Younossi. Gene Expression Profile Associated with Hepatic Stellate Cells: Implications for Hepatic Fibrosis. Dig Dis Sci. 2010; 55:496-504

ABSTRACTS AND PRESENTATIONS TO INTERNATIONAL MEETINGS:

Presentations Related to Non-Alcoholic Fatty Liver Disease and Obesity:

1. Z Younossi, T Gramlich, G Liu, M Pettrelli, J Goldblum, L Rybicki, C Matteoni, AJ McCullough. Assessment of Observer Variability on Pathologic Interpretation of Non-Alcoholic Steatohepatitis. American Association for Study of Liver Disease, Chicago 1997.
2. Z Younossi, C Matteoni, T Gramlich, G Liu, L Rybicki, AC McCullough. Clinico-Pathologic Outcomes in Non-Alcoholic Steatohepatitis. American Association for Study of Liver Disease. Chicago 1998.
3. C Matteoni, Z Younossi, T Gramlich, G Liu, L. Rybicki, AC McCullough. Non-Alcoholic Steatohepatitis: Risk Factors and Outcomes. Digestive Disease Week. New Orleans 1998
4. C Matteoni, Z Younossi, T Gramlich, G Liu, L. Rybicki, AC McCullough. Non-Alcoholic Steatohepatitis: Risk Factors and Outcomes. Digestive Disease Week. New Orleans 1998.
5. C Matteoni, Z Younossi, TG Gramlich, Y Liu, N Boparai, D Wohl, AJ McCullough. Histologic Iron is Not Increased in Non-Alcoholic Steatohepatitis. American Association for Study of Liver Disease. Chicago 1998.
6. Z Younossi, CA Matteoni, T Gramlich, Y Liu, N Boparai, D Wohl, AJ McCullough. Patient Characteristics Predicting Cirrhosis in Non-Alcoholic Steatohepatitis and Death in Non-Alcoholic Steatohepatitis. American Association for Study of Liver Disease. Chicago 1998
7. Z Younossi, CA Matteoni, TL Gramlich, N Boparai, L Price, AJ McCullough. Diabetes and Non-Alcoholic Fatty Liver Disease: A Worrisome Combination. Digestive Disease Week, Orlando, FL. Gastroenterology, Vol. 116 (No.4): 1292, 1999.
8. Z Younossi, TL Gramlich, BR Bacon, CA Matteoni, N Boparai, R O'Neill, AJ McCullough. Iron in Non- Alcoholic Fatty Liver Disease: Myth or Reality? Digestive Disease Week. Orlando, FL. Gastroenterology, Vol. 166 (No.4): 1293, 1999.
9. Z Younossi, DE Kleiner for the NIDDK's Non-alcoholic Steatohepatitis Pathology Working Group, T Gramlich, N Boparai. Application of NIDDK Non-alcoholic Steatohepatitis Pathologic Protocol to Patients with Non-Alcoholic Fatty Liver Disease. Digestive Disease Week. San Diego, CA. 2000
10. J Ong, V Reddy, T Gramlich, LL Price, N Boparai, Z Younossi. Cryptogenic Cirrhosis and Risk of Recurrent Non-Alcoholic Fatty Liver Disease Post-Liver Transplantation. Digestive Disease Week. San Diego, CA. 2000.
11. C Speer, J Ong, N Boparai, T Gramlich, Z Younossi. Chronic Hepatitis C: Association of Fat and Fibrosis. Oral Presentation. Digestive Disease Week. San Diego, CA. 2000.
12. S Saadeh, Z Younossi, E Remer, T Gramlich, K Mullen, J Cooper, M Sheridan. The Utility of Radiologic Assessments with CT, US and MRI in Establishing the Diagnosis of Non-Alcoholic Fatty

- Liver Disease. American Associate for the Study of Liver Diseases. Dallas, TX 2001. Hepatology, Vol.34 (No.4) Pt 2. 2001.
13. E Remer, S Saadeh, T Gramlich, J Ong, M Hurley, J Cooper, M Sheridan, Z Younossi. Variability of Radiologic Assessments in Non-Alcoholic Fatty Liver Disease (Non-alcoholic Fatty Liver). Poster with Distinction. Digestive Disease Week. San Francisco, CA. May 2002.
 14. H Gujral, M Erario, G Anaya, J Ong, Z Younossi. Current Clinical Approaches to the Role of Liver Biopsy in Non-Alcoholic Fatty Liver Disease. Digestive Disease Week. (Oral Presentation). San Francisco, CA. May 2002.
 15. J Ong, A Younoszai, H Elariny, Z Goodman, N Boparai, A Christensen, G Grant, V Chandhoke, J Cooper, Z Younossi. High Prevalence of Non-Alcoholic Steatohepatitis (Non-alcoholic Steatohepatitis) in Morbidly Obese Patients: Discordance between Elevated Liver Enzymes and Histology. Digestive Disease Week. San Francisco, CA. May 2002.
 16. J Ong, H Elariny, A Younoszai, Z Goodman, G Grant, A Christensen, V Chandhoke, J Cooper, N Bopari, Z Younossi. Predictors of Non-Alcoholic Steatohepatitis and Fibrosis in Non-Alcoholic Fatty Liver Disease. American Association for Study of Liver Disease. Boston, MA. November 2002.
 17. A Younoszai, J Ong, G Grant, L Del Giacco, F Gorreta, H Elariny, Z Goodman, A Christensen, C Jamison, V Chandhoke, Z Younossi. Genomics of the Spectrum of Non-Alcoholic Fatty Liver Disease. American Association for Study of Liver Disease. Boston, MA. November 2002.
 18. G Grant, J Ong, F Gorreta, L Del Giacco, H Elariny, A Younoszai, Z Goodman, A Christensen, C Jamison, V Chandhoke, Z Younossi. Genetic Epidemiology of Non-Alcoholic Steatohepatitis. American Association for Study of Liver Disease. Boston, MA. 2002.
 19. ZM Younossi, AJ McCullough, JP Ong, DS Barnes, A Post, KD Mullen, WD Carey, R O'Shea, G Levinthal, T Gramlich, L Martin, D Bringman, AS Tavill, DR Ferguson. Interaction of Steatosis and Non-Alcoholic Steatohepatitis (Non-alcoholic Steatohepatitis) with Chronic Hepatitis C. Digestive Disease Week. Orlando, FL. May 2003.
 20. T Born, J Ong, K Schlauch, H Elariny, A Younoszai, Z Goodman, A Christensen, J Assmann, V Chandhoke, ZM Younossi. Insulin Resistance, Serum Leptin and Fibrosis in Non-Alcoholic Fatty Liver Disease (Non-alcoholic Fatty Liver). Digestive Disease Week. Orlando, FL. May 2003.
 21. K Schlauch, J Ong, L del Giacco, F Goretta, G Grant, H Elariny, A Younoszai, Z Goodman, A Christensen, V Chandhoke, ZM Younossi. The Impact of Anti-Diabetic Medications on the Gene Expressions of Diabetics with Non-Alcoholic Fatty Liver Disease. Digestive Disease Week. Orlando, FL. May 2003.
 22. J Ong, K Schlauch, L del Giacco, F Goretta, G Grant, H Elaring, A Younoszai, Z Goodman, A Christensen, V Chandhoke, ZM Younossi. The Impact of Insulin-Resistance on the Genomics of Non-Alcoholic Fatty Liver Diseases (Non-alcoholic Fatty Liver). Digestive Disease Week. Orlando, FL. May 2003.
 23. K Schlauch, G Grant, J Ong, V Chandhoke, A Christensen, Z Younossi. A Genomic Study of Non-Alcoholic Fatty Liver Disease. Informatics, Microarray Data Analysis Conference. Zurich, Switzerland. February 2003.
 24. K Miller, T Born, JP Ong, A Younoszai, H Elariny, K Schlauch, Z Goodman, Z Younossi. Proteomics of Non-Alcoholic Steatohepatitis (Non-alcoholic Steatohepatitis): Analysis of Protein Expression Profiles Using SELDI-TOF Mass Spectrometry. American Association for Study of Liver Disease. Boston, MA. October 2003.
 25. A Mehrota, Z Goodman, H Elariny, A Younoszai, N Bopari, J Assmann, V Chandhoke, Z Younossi. The Utility of Immunostaining for Mallory Bodies in Non-Alcoholic Fatty Liver Disease. American Association for Study of Liver Disease. Boston, MA. October 2003.
 26. F Gorreta, L Del Giacco, K Schlauch, A VanMeter, G Grant, A Christensen, V Chandhoke, Z Goodman, A Younoszai, H Elariny, JP Ong, Z Younossi. Gender Differences in Hepatic Gene Expression of Patients with Non-Alcoholic Steatohepatitis (Non-alcoholic Steatohepatitis). American Association for Study of Liver Disease. Boston, MA. October 2003.

27. K Schlauch, L O'Reilly, T Born, K Miller, J Ong, H Elariny, F Gorreta, L Del Giacco, A Younoszai, G Grant, V Chandhoke, Z Goodman, Z Younossi. A Genomic and Proteomic Study of Obesity-Related Non-Alcoholic Fatty Liver Disease. European Association for the Study of Liver Diseases. 2004.
28. S Nazarenko, A Baranova, H Elariny, K Schlauch, A Younoszai, S Gowder, T Alsheddi, F Goretta, O Court, D Reines, V Chandhoke, Z Younossi. Gene Expression Profiles Associated with Obesity. Digestive Disease Week. 2004.
29. V Chandhoke, A Baranova, S Nazarenko, H Elariny, K Schlauch, A Younoszai, S Gowder, T Alsheddi, S Pusulury, F Goretta, J Assmann, L Martin, Z Younossi. Gene Expression Profiles in Omental Adipose Tissue of Morbidly Obese Patients. Human Genome Meeting. 2004.
30. K Schlauch, J Ong, L Del Giacco, F Goretta, H Elariny, A Younoszai, A Christensen, V Chandhoke, Z Younossi. Hepatic Gene Expression Profile Related to the Metabolic Syndrome. Human Genome Meeting. 2004.
31. K Schlauch, F Gorreta, T Born, H Elariny, L Del Giacco, K Ziegler, A Van Meter, J. Ong, V Chandhoke, R Collantes, Z Goodman, Z Younossi. Hepatic Gene Expression and Serum Protein Profile of Patients with Metabolic Syndrome. Association for Study of Liver Disease. Boston, MA. October 2004.
32. Z Younossi, J Ong, H Elariny, F Gorreta, L Del Giacco, K Ziegler, T Born, K Schlauch, A Van Meter, R Collantes, A Baranova, G Grant, Z Goodman, V Chandhoke. Hepatic Gene Expression and Serum Protein Profile of Patients with Obesity-Related Non-Alcoholic Steatohepatitis (Non-alcoholic Steatohepatitis). North American Association for the Study of Obesity's Annual Scientific Meeting. Las Vegas, NV. November 2004.
33. J Ong, H Elariny, A Younoszai, R Collantes, Z Goodman, V Chandhoke, Z Younossi. Non-Alcoholic Steatohepatitis in Morbidly Obese Patients. Annual Scientific Meeting. North American Association for the Study of Obesity's. Las Vegas, NV. November 2004.
34. G-H Wang, A Mehrotra, JP Ong, ZM Younossi, Z Goodman. P62 as a Reliable Marker for Mallory Bodies in Non-Alcoholic Steatohepatitis (Non-alcoholic Steatohepatitis). United States and Canadian Academy of Pathology Annual Meeting, Washington DC, 2005.
35. A Baranova, R Collantes, K Schlauch, H Elariny, S Gowder, A Afendy, J Ong, Z Goodman, V Chandhoke, Z Younossi. Adiponectin Gene Expression in the Intra-Abdominal Adipose Tissue Of Patients With Non-Alcoholic Fatty Liver Disease: Diabetics Vs. Non-Diabetics. Digestive Disease Week 2005.
36. S Gowder, K Schlauch, A Van Meter, R Collantes, V Chandhokw, ZM. Younossi, A Baranova. Melanin Biosynthesis Pathway Is Functional In Fat Tissue Collected From Morbidly Obese Patients. 19th International Pigment Cell Conference – “A Focus on Human Pigmentary Diseases” 2005.
37. A Baranova, S Gowder, R Collantes, H Elariny, K Schlauch, A Afendy, JP Ong, Z Goodman, V Chandhoke, ZM Younossi. Serum Adipokines And The Associated Gene Expression In The Adipose Tissue Of Obese Patients With And Without Insulin Resistance Cytokine Meeting Toronto, CA, Digestive Disease And Sciences, Vol 50, Nr 10:1962, 2005
38. R Collantes, A Baranova, H Elariny, S Gowder, L Del Giacco, K Schlauch, A VanMeter, Arian Afendy, JP Ong , Z Goodman, V Chandhoke, ZM Younossi. Gene Expression In Hepatic And White Adipose Tissues Of Patients With Obesity-Related Non-Alcoholic Steatohepatitis. European Association for the Study of Liver Disease Vienna, Austria. 2006.
39. M Emblom-Callahan, SD Nathan, GM Grant, J Estep, S Ahmad, M Sulkowski, A Afendy, NB Burton, V Chandhoke, Z Younossi. Gene Expression Analysis of Myofibroblasts in End Stage Lung Disease: Implications For DNA Repair. American Thoracic Society Meeting (Oral Presentation) 2006.
40. VS Calvert, R Collantes, H Elariny, A Baranova, A Afendy, Z Goodman, L Liotta, E Petricoin, and ZM. Younossi. Signal Pathway Proteomic Analysis of Human Adipose Tissue using Phosphoprotein Arrays: Insights into the Pathophysiology of Nonalcoholic Fatty Liver Disease and type 2 Diabetes (DM). Digestive Disease Week Los Angeles, CA. 2006 (Oral Presentation)

41. A Baranova, N. Ad, S. Gowder, H. Elariny, S Younossi, M. Jarrar, R. Collantes, V. Chandhoke, Z. Younossi. Serum Adiponectin and Resistin in Non-alcoholic Fatty Liver Diseases and Arteriosclerosis. Digestive Disease Week. Los Angeles, CA. 2006.
42. VS. Calvert, R Collantes, H Elariny, A Baranova, A Afendy, Z Goodman, L Liotta, ZM. Younossi, E Petricoin. Signal Pathway Proteomic Analysis of Human Adipose Tissue using Phosphoprotein Arrays: Insights into the Pathophysiology of Nonalcoholic Fatty Liver Disease and type 2 Diabetes (DM). HUPO Meeting 2006 (Oral Presentation)
43. ZM Younossi, M Singer. Lifetime Medical and Economic Impact of Patients with Non-Alcoholic Fatty Liver Disease in the United States (US). Association for Study of Liver Disease. Boston, MA. 2006.
44. V Calvert, R Collantes, H Elariny, A Afendy, A Baranova, M Mendoza, Z Goodman, L Liotta, E Petricoin, ZM Younossi. Distinguishing Progressive Fatty Liver Disease from the Non-Progressive Form Using Reverse Phase Phosphoproteomic Array Analysis of Intracellular Signaling Pathways. AASLD Meeting . Boston, MA.2006. (Oral Presentation).
45. JP Ong, A Pitts, ZM Younossi. The Impact of Nonalcoholic Fatty Liver Disease on Mortality. A Population-based Cohort Study. Association for Study of Liver Disease, Boston, MA.2006.
46. S Bondini, T Gramlich, L Ramsey, JP Ong, D Jondle, N Boparai, H Gujral, ZM Younossi. The Impact of Non-alcoholic Fatty Liver Disease on Chronic Hepatitis B. The Impact of
47. Z Younossi. Non-alcoholic Fatty Liver Disease on Chronic Hepatitis B. Association for Study of Liver Disease, Boston, MA. 2006.
48. V Calvert, R Collantes, H Elariny, A Afendy, A Baranova, M Mendoza, Z Goodman, L Liotta, E Petricoin, ZM Younossi. Insight into the Spectrum of Non-alcoholic Fatty Liver Disease Using Phosphoproteomic Array Analysis of Intracellular Signaling from Human Adipose Tissue. HUPO International Meeting 2006 (Oral Presentation).
49. M Jarrar, B Ranard, M Stepanova, C Nugent, H Elariny, C Bennett, R Collantes, Z Goodman, V Chandhoke, A Baranova, ZM Younossi. Hepatic Manifestation of Metabolic Syndrome: Non-alcoholic Fatty Liver Disease and Serum Adipokines. EASL, Barcelona. 2007.
50. A Baranova, M Jarrar, M Mendoza, H Elariny, R Collantes, B Ranard, K Schlauch, M Stepanova, Z Goodman, V Chandhoke, ZM Younossi, A Role Of The Pro-Inflammatory Background In The Development Of Non-Alcoholic Fatty Liver Disease. Keystone Conference. 2007.
51. V Calvert, R Collantes, H Elariny, A Afendy, A Baranova, C Nugent, Y Fang, J Deng, Z Goodman, L Liotta, E Petricoin, Z Younossi. Can Phosphoproteomic Analysis of White Adipose Tissue (WAT) Predict Presence of Insulin Resistance (IR) and Resolution of Diabetes Mellitus (DM) in Non-alcoholic Fatty Liver Disease? Digestive Disease Week, Washington DC, 2007
52. P Mishra, C Nugent, A Afendy, A Wheeler, CH Bai, P Bhatia, Y Fang, ZM Younossi Apneic-Hypopneic Episodes During Obstructive Sleep Apnea Can be Associated with Histologic Nonalcoholic Steatohepatitis (Non-alcoholic Steatohepatitis) Digestive Disease Week. Washington, D.C. 2007.
53. M Jarrar, H Elariny, R Collantes, C Nugent, Y Fang, M Stepanova, N Kopparti, Z Goodman, V Chandhoke, A Baranova, ZM Younossi Is Visfatin A Protective Adipoikine in Patients with Non-alcoholic Fatty Liver Disease Digestive Disease Week. Washington, D.C. 2007.
54. VS Calvert, C Nugent, R Collantes, H Elariny, A Afendy, A Baranova, Y Fang, J Deng, Z Goodman, L Liotta, E Petricoin, Z Younossi. Phosphoproteomic Biomarkers Predicting Weight Loss After Bariatric Surgery in Patients with Non-alcoholic Fatty Liver Disease. American Association for Study of Liver Disease, Boston, MA, 2007.
55. A Baranova, M Jarrar, C Nugent, A Afendy, C Quigley, M Stepanova, H Elariny, Z Goodman, V Chandhoke, Z Younossi. Non-invasive Diagnostic Biomarkers for Non-alcoholic Steatohepatitis (Non-alcoholic Steatohepatitis). American Association for Study of Liver Disease, Boston, MA, 2007.

56. CH. Kim, J.B. Kallman, R. Srivastava, R. Gupta, A. Murthy, M.E. Sabatella, L. Pawloski, Z.M. Younossi. Nutritional Assessment Of Patients With Non-Alcoholic Fatty Liver Disease And Chronic Viral Hepatitis. Association for Study of Liver Disease, Boston, MA, 2007.
57. CH Bai, C Nugent, M Garone, P Gopalakrishnan, C Quigley, Z Younoszai, M Afendy, R Collantes, M Srishord, H Elariny, ZM Younossi. Improvement of Metabolic Syndrome (MS) in Patients with Non-alcoholic Fatty Liver Disease After Bariatric Surgery. American College of Gastroenterology, Philadelphia, PA, 2007
58. Z Younossi, A Baranova, A Afendy, M Stepanova, N Hossain, I Younossi, K Ankrah, M Srishord, C Santini, J Chan, SY Chang. Gene Expression Associated with Hepatic Steatosis in Patients with Chronic Hepatitis C Genotype 1 (Poster with Distinction). Digestive Disease Week. San Diego, CA, 2008.
59. J Kallman, A Arsalla, A Wheeler, R Aquino, K Terra, R Euliano, ZM Younossi. The Impact of Hepatitis B (HBV), Hepatitis C and Non-Alcoholic Fatty Liver Disease Guidelines on Clinical Practices. Digestive Disease Week (Poster with Distinction). San Diego, CA, 2008.
60. N Rafiq, C Bai, Y Fang, M Srishord, A McCullough, ZM Younossi. Over Twenty Five Years of Follow up for A Non-alcoholic Fatty Liver Disease Cohort. (Oral Presentation). Digestive Disease Week. San Diego, CA, 2008.
61. W Dunn, R Xu, D Wingard, C Rogers, P Angulo, ZM. Younossi MD, JB. Schwimmer. Suspected Nonalcoholic Fatty Liver Disease and Mortality Risk in a Population-based Cohort Study. Digestive Disease Week. San Diego, CA, 2008.
62. Z Younossi, M Jarrar, C Nugent, M Randhawa , M Afendy, M Stepanova, A Afendy, N Rafiq, Z Goodman, V Chandhoke, A Baranova. Validation of A Diagnostic Biomarker Panel for Non-alcoholic Steatohepatitis (Non-alcoholic Steatohepatitis). (Oral Presentation). European Association for the Study of Liver, Milan, Italy 2008.
63. J Ong, A Pitts, Z Younossi. Non-Alcoholic Fatty Liver Disease Is Associated With Higher Overall Mortality And Liver Related Mortality. (Oral Presentation, Plenary Session). European Association for the Study of Liver, Milan, Italy 2008.
64. C Bai, C Nugent, H Elariny, P Gopalakrishnan, C Quigley, M Garone Jr., M Afendy, O Chan, A Wheeler, A Afendy , A Arsalla, ZM. Younossi. The Impact Of Laparoscopic Bariatric Surgery On Components Of Metabolic Syndrome. Annual Meeting of American Society for Metabolic & Bariatric Surgery. Washington DC. 2008
65. N Rafiq, R Gupta, R Aquino, JB. Kallman, M Garone, Y Fang, A Murthy, SAhmad, S Dhungel, S Kumar, C Quigley, N Hossain, A Alsheddi, CH Kim, ZM Younossi. Components of Metabolic Syndrome and Type 2 Diabetes are Associated with Advanced Liver Disease. (Poster Presentation). American College of Gastroenterology, Orlando, FL 2008.
66. M Stepanova, A Baranova, Hazem Elariny, Nila Rafiq, Arian Afendy, Vikas Chandhoke, Zobair M Younossi. American Association For Study Of Liver Disease. San Francisco, CA 2008
67. J Michael Estep, Kathy Ankrah, Hazem Elariny, Yun Fang, Vikas Chandhoke, Ancha Baranova, Zobair M. Younossi. Inflammatory Cytokine Gene Expression in the Visceral Adipose Tissue of NASH Patients with Type II Diabetes and/or Fibrosis. Mid-Atlantic Diabetes Symposium, National Institutes of Health, Bethesda, MD 2008
68. M Stepanova, A Baranova, H Elariny, N Rafiq, A Afendy, V Chandhoke, ZM Younossi, Differences In Hepatic Gene Expression Of Caucasians And African American Patients With Non-Alcoholic Fatty Liver Disease (NAFLD) American Association For Study Of Liver Disease. San Francisco, CA 2008
69. JM Estep, K Ankrah, H Elariny, I Kaur, Y Fang, V Chandhoke, A Baranova, ZM Younossi. Cytokine Signaling Gene Expression In The Adipose Tissue Is Associated With Fibrotic Changes In Patients With Non-Alcoholic Fatty Liver Disease (NAFLD) American Association For Study Of Liver Disease. San Francisco, CA 2008

70. Nila Rafiq, Maria Stepanova, Brian Lam, and Zobair M. Younossi. Type 2 Diabetes, Obesity And Hypertension Are Associated With Mortality In Hepatitis C Patients. European Association for the Study of Liver, Copenhagen, Denmark 2009 (Oral Presentation)
71. Zobair M. Younossi, Ancha Baranova, Maria Stepanova, Valerie S. Calvert, Arian Afendy, Zachary Goodman, Lance Liotta, Emanuel Petricoin. Proteomics Biomarkers Predicting Histologic Non-Alcoholic Steatohepatitis And Fibrosis. European Association for the Study of Liver, Copenhagen, Denmark 2009
72. Ancha Baranova, Nila Rafiq, Ishmeet Kaur, Noreen Hossain, Manpreet Randhawa, Vikas Chandhoke, Zobair M. Younossi. Differences of Adipocytokine Between Non-Alcoholic Fatty Liver Disease And Coronary Artery Disease. European Association for the Study of Liver, Copenhagen, Denmark 2009
73. Stepanova, Maria, Rafiq, Nila; Mir, Hesham M.; Bornman, Ine-Mari; Younossi, Zobair M. Mortality and Liver Related Mortality in Patients with Chronic Liver Disease: Association with Components of Metabolic Syndrome (MS) Digestive Disease Week, Chicago, Illinois, 2009 (Oral Presentation).
74. Hossain, Noreen; Afendy, Arian; Stepanova, Maria; Rafiq, Nila; Nader, Fatema; Srishord, Manirath K.; Goodman, Zachary D.; Younossi, Zobair M. Independent Predictors of Fibrosis in a Large Cohort of Patients with Non-Alcoholic Fatty Liver Disease. Digestive Disease Week, Chicago, Illinois, 2009.
75. Estep, Michael; Biredinc, Aybike; Wheeler, Angela M.; Page, Sandy; Stepanova, Maria; Baranova, Ancha; Alathari, Husam K.; Younossi, Zobair M. Carbohydrate-Deficient Transferrin in Patients with Fatty Liver Disease. Submitted to Obesity Meeting 2009.
76. Garone, Michael; Kallman, Jillian; Aquino, Ruben D. ; Fang, Yun; Lee, Phuong; Elariny, Hazem A.; Younossi, Zobair M. Activity Level in Patients Undergoing Bariatric Surgery. Digestive Disease Week, Chicago, Illinois, 2009.
77. M Stepanova, A Wheeler, J Kallman, H Alathari, H Elariny, Y Fang, N Hossain, N Rafiq, Z Younossi . Psychiatric Disorders in Patients Undergoing Bariatric Surgery. The Obesity Society's Annual Scientific Meeting, Washington DC, Oct 2009
78. D Armistead, M J. Estep, M Stepanova, G Manyam, N Rafiq, H Elariny, A Baranova, ZD. Goodman, ZM. Younossi' Differential Expression of miRNA in Patients with Non-alcoholic Steatohepatitis. American Association For Study Of Liver Disease 2009, Boston MA
79. M Estep, ABiredinc, AWheeler, S Page, A Baranova, HAlathari, Z Younossi. Carbohydrate-Deficient Transferrin in Patients with Fatty Liver Disease Undergoing Bariatric Surgery. The Obesity Society's Annual Scientific Meeting, Washington DC, Oct 2009
80. ZM. Younossi, N Rafiq, S Page, M Stepanova, N Hossain, A Biredinc, ZD. Goodman, A Baranova. A Novel Serum-based Biomarker Panel for Non-alcoholic Steatohepatitis (NASH) and NASH-related Fibrosis. American Association For Study Of Liver Disease 2009, Boston MA
81. Noreen Hossain, Maria Stepanova, Arian Afendy, Fatema Nader, Nila Rafiq, Zachary D. Goodman, Zobair M. Younossi. Non-alcoholic Steatohepatitis (NASH) in Patients with Polycystic Ovarian Syndrome (PCOS). American Association for Study Of Liver Disease 2009, Boston MA.
82. Sandra Page, Nila Rafiq, Maria Stepanova, Arian Afendy, Aybike Biredinc, Zachary D. Goodman, Ancha Baranova, Zobair M. Younossi. Comparison of Different Biomarkers for Patients with Non-alcoholic Steatohepatitis. American Association for Study of Liver Disease 2009, Boston MA.
83. J M Estep, D. Armistead, M Stepanova, N. Hossain, H. Elariny, A Baranova, Z Goodman, V Chandhoke, Z Younossi. Serum Cytokines and the Expression of miRNAs in the Visceral Adipose of Patients with Non-alcoholic Fatty Liver Disease. European Association for the Study of Liver Disease Meeting 2010. Oral Presentation
84. M Stepanova, D Limongi, A Afendy, M Pierobon, I Younossi, T Gramlich, L Liotta, E Petricoin, Z Younossi. Protein Pathway Biomarkers Signature Associated with Superimposed Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis in Patients with Chronic Hepatitis C. European Association for the Study of Liver Disease, 45th Annual Meeting 2010, Vienna, Austria.

85. R Mehta, A Birerdinc, N Hossain, A Moazez, V Chandhoke, A Baranova, ZM Younossi. Profiling and Validation of Reference Genes in the Visceral Adipose Tissue (VAT). Digestive Disease Week, Annual Meeting 2010, New Orleans, Louisiana
86. A Birerdinc, R Mehta, N Hossain, B Yaquab, H Elariny, A Baranova, V Chandhoke, Z Younossi. Differential Gene Expression Profiling of Brown Adipose Tissue (BAT) Specific Genes in Visceral Adipose Tissue of Lean and Obese Individuals. Digestive Disease Week, Annual Meeting 2010, New Orleans, Louisiana
87. D Desai, M Estep, A Birerdinc, H Mir, A Baranova, V Chandhoke, Z Younossi. Markers of Insulin Resistance during HCV Treatment: A Relationship to Sustained Virologic Response (SVR). Digestive Disease Week, Annual Meeting 2010, New Orleans, Louisiana
88. M Estep, M Abawi, S Bolden, M Stepanova, N Hossain, Z Goodman, V Chandhoke, A Baranova, Z Younossi. Serum Obestatin Concentrations in Non-alcoholic Fatty Liver Disease (NAFLD) with Fibrosis. Digestive Disease Week, Annual Meeting 2010, New Orleans, Louisiana (Submitted).
89. M Stepanova, G Mayam, N Hossain, V Chandhoke, A Baranova, Z Goodman, Z Younossi. Functional Pathway Analysis of Gene Expression in Patients with Non-alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH). (Top 15% Poster Presentation) European Association for the Study of Liver Disease, 45th Annual Meeting 2010, Vienna, Austria.
90. S Page, N Rafiq, A Birerdinc, M Stepanova, N Hossain, A Afendy, Z Younoszai, Z Goodman, A Baranova, ZM. Younossi A Biomarker Panel for Non-alcoholic Steatohepatitis (NASH) and NASH-Related Fibrosis (Oral Presentation). Virginia Academy of Science 2010, Harrisonburg, Virginia.
91. M. Abawi, A. Zirzow, M. Estep, N. Hossain, H. Elarainy, Z. Goodman, V. Chandhoke, Z. Younossi, A. Baranova Alpha-Melanin Stimulating Hormone (αMSH) and Melanin Concentrating Hormone (MCH) Expression in Obesity and Obesity Related Disease (Oral Presentation). Virginia Academy of Science 2010, Harrisonburg, Virginia.
92. Rohini Mehta, Aybike Birerdinc, Noreen Hossain, Arian Afendy, Vikas Chandhoke, Zobair Younossi, Ancha Baranova, Endogenous reference gene validation for qRT - PCR studies on human visceral adipose tissue (Oral Presentation). Virginia Academy of Science 2010, Harrisonburg, Virginia.
93. Nandita Niranjani, Ancha Baranova, Zobair Younossi, Aybike Berendinc. Role of Insulin Resistance in PCOS and Implications for Development of Metabolic syndrome and Hepatic Steatosis (Oral Presentation). Virginia Academy of Science 2010, Harrisonburg, Virginia.
94. A. Zirzow, M. Estep, N. Hossain, H. Elarainy, Z. Goodman, V. Chandhoke, A. Baranova, Z. Younossi. Expression of Cytokines and Cytokine Receptors in Morbidly Obese Patients with Non-alcoholic fatty liver disease (Oral Presentation). Virginia Academy of Science 2010, Harrisonburg, Virginia.
95. E Eom, A Birerdinc, A Baranova, ZM Younossi Preservation of Serum and mRNA Samples For Downstream High Throughput Studies. Virginia Academy of Science 2010, Harrisonburg, Virginia.
96. Maria Stepanova, Manirath Srishord, Fatema Nader, Zobair M. Younossi. Insulin Resistance (IR) and Type II Diabetes (DM) Are Independent Predictors of Overall and Liver-Related Mortality in Non-alcoholic Fatty Liver Disease (NAFLD) and Alcohol-related Liver Disease (ALD): A Population-Based Study. American Association for Study of Liver Disease 2010, Boston MA
97. Nila Rafiq, Hala R. Makhlof, Ritambhara Agrawal, Ishmeet Kaur, Zahra Younoszai, Maria Stepanova, Zachary Goodman, Zobair M. Younossi. Long Term Mortality Outcomes in Patients with Biopsy-Proven Non-alcoholic Fatty Liver Disease. American Association for Study of Liver Disease 2010, Boston, MA
98. Hossain, Noreen, Stepanova, Maria, Younossi, Youssef, Fang, Yun, Raybuck, Bryan, Younossi, Zobair M. High Prevalence of Coronary Artery Disease (CAD) in Patients with Non-alcoholic Fatty Liver Disease (NAFLD). American College of Gastroenterology, Annual Meeting 2010, San Antonio, Texas
99. Alhussain, Reem, Rohini Mehta, Birerdinc, Aybike, Hossain, Noreen, Baraki, Yaquab; Elariny, Hazem, Chandhoke, Vikas; Baranova, Ancha, Younossi, Zobair M. Profiling and Validation of

- Reference Genes in the Gastric Tissue of Morbidly Obese Patients. American College of Gastroenterology, Annual Meeting 2010, San Antonio, Texas
100. Michael Estep, Amanda Zirzow, Maria Stepanova, Noreen Hossain, Yaqub Barakai, Hazem Elarainy, Amir Moazez, Zachary Goodman, Vikas Chandhoke, Ancha Baranova, Zobair Younossi. Baseline Serum Obestatin Correlates with Rate of Weight Loss after Bariatric Surgery. American College of Gastroenterology, Annual Meeting 2010, San Antonio, Texas

Presentations Related to Quality of Life Research:

101. Z Younossi, M Kiwi, D King, G Guyatt. A Liver Disease-Specific Health Related Quality of Life Index: Chronic Liver Disease Questionnaire (CLDQ). American Association for Study of Liver Disease. Chicago 1997.
102. Z Younossi, M Kiwi, M Secic, G Guyatt. Health Related Quality of Life in Chronic Liver Disease. Digestive Disease Week. New Orleans 1998.
103. Z Younossi, M O'Neil, M Kiwi, M Secic, L Calabrese. Hepatitis C: Rheumatologic, Health Related Quality of Life, Virologic and Histologic Outcomes. Digestive Disease Week. New Orleans 1998.
104. Z Younossi, ML Kiwi, N Boparai. Reduction of Health-Related Quality of Life in Patients Infected with Hepatitis C. Oral presentation. International Society for Quality of Life Research. Baltimore, MD 1998.
105. Z Younossi, N Boparai, ML Kiwi, L Farquhar, M McCormick, G Guyatt. Can Quality of Life Predict Resource Utilization in Liver Transplant Candidates. American Association for Study of Liver Disease. Chicago 1998.
106. Z Younossi, N Boparai, ML Kiwi, M McCormick, G Guyatt. Extensive Evaluation of Quality of Life in a Large Cohort of Patients with a Variety of Chronic Liver Disease. American Association for Study of Liver Disease. Chicago 1998.
107. Z Younossi, ML Kiwi, M McCormick, N Boparai, G Guyatt. Performance of a New Disease-Specific Quality of Life Instrument in Cholestatic Liver Disease. American Association for Study of Liver Disease. Chicago 1998.
108. D Miller, Z Younossi, M Kiwi, N Boparai. Short Form 36 Performance with Worsening Severity of Disease: Chronic Liver Disease and Multiple Sclerosis. International Society for Quality of Life Research. Baltimore, MD 1998.
109. Z Younossi, M McCormick, N Boparai, L Price, G Guyatt. Health-Related Quality of Life Measured by Generic, Disease-Specific and Utility Instruments. American Association for Study of Liver Disease, 1999.
110. Z Younossi, M McCormick, N Boparai, L Price, G Guyatt. Impact of Chronic Liver Disease on Patients' Utilities. Digestive Disease Week, Orlando, FL. Gastroenterology, Vol. 116 (No.4): 1293, 1999.
111. Z Younossi, G Marchesini for the Italian Study Group for HRQL in Cirrhosis, N Boparai, L Price, M McCormick. Health-Related Quality of Life in Over 1000 Patients with Chronic Liver Disease: The Impact of Age, Gender, Culture, Severity and Type of Liver Disease. American Association for Study of Liver Disease. Dallas, TX. 1999.
112. Z Younossi, N Boparai, M McCormick. A Disease-Specific Health-Related Quality of Life Instrument for Chronic Hepatitis C: CLDQ-HCV. American Association for Study of Liver Disease. Dallas, TX. 2000.
113. L Martin, Z Younossi, L Price, A McCullough, J Ong, M Srishord, N Boparai. The Impact of Ribavirin-Induced Anemia on Health-Related Quality of Life. Martin L, et al. Hepatology.;34: pt 2. Abstract 1711. 2001.
114. Z Younossi, L Martin, N Afdhal, A McCullough, M Sheridan. The Impact of Obesity, Gender and Age on Health-Related Quality of Life Using the HCV Specific HRQL Instrument. Hepatology, Vol. 34 (No.4) Pt 2. 2001.

115. Z Younossi, L Martin, M McCormick. Impact of Ascites on Health-Related Quality of Life European Association for the Study of Liver Diseases, Monothematic Conference. London, UK. June 2002.
116. L Martin, D Bringman, R Joseph, R Ghanta, JP Ong, C Crone, G Herman, A McCullough, Z Younossi. Depression, Interferon Alpha (IFN) and Health Related Quality of Life (HRQL) in Chronic Hepatitis C (CH-C). American Association for Study of Liver Disease. Boston, MA. October 2003.
117. N Afdhal, G Leitz, L Tang, Z Younossi. Hemoglobin Increase is Independently Associated with Increased Health-Related Quality of Life (HRQL) in Anemic Interferon/Ribavirin (IFN/RBV)-Treated Hepatitis C Virus (HCV)-Infected Patients Treated with Epoetin Alfa. American Association for Study of Liver Disease. Boston, MA. October 2003.
118. N Afdhal, G Leitz, S Mody, Z Younossi. Epoetin Alfa (EPO) Improves and Maintains Health-Related Quality of Life (HRQL) in Anemic HCV-Infected Patients Receiving Interferon/Ribavirin (IFN/RBV): HRQL Results from the Proactive Study. American Association for Study of Liver Disease. Boston, MA. October 2003.
119. B Spiegel, ZM. Younossi, RD Hayes, D Revicki, S Robbins, F Kanwal, The Impact of Hepatitis C on Health Related Quality of Life: A Systematic Review and Quantitative Assessment. Digestive Disease Week 2005.
120. J Kallman, A Dan, A Wheeler, Z Younoszai, S Bondini, L Gerber, ZM Younossi. Health-related Quality of Life (HRQL) in Patients with Non-alcoholic Fatty Liver Disease. Association for Study of Liver Disease, Boston, MA. 2006.
121. B Spiegel, R Bolus, M Tong, E Esralian, J Talley, T Tran, J Smith, H Karsan, F Durazo, B Bacon, P Marin, Z Younossi S Hwa Ong, F Kanwal. Development and Validation of a Disease-Targeted Health Related Quality of Life in Chronic Hepatitis B Infection: The HBQOL V1.0, Association for Study of Liver Disease, Boston, MA. 2006.
122. A Dan, J Kallman, R Srivastava, Z Younoszai, A Kim, ZM Younossi Health Utility Assessment Using SF-6D and Health Utility Index (HUI) in Patients with Chronic Liver Disease. Digestive Disease Week. Washington DC, 2007
123. J Kallman, A Afendy, M Stepanova, Maria, Younoszai, Zahra, Aquino, Ruben D, Bianchi, Giampaolo, Marchesini, Giulio, Younossi, Zobair M. Health-relate Quality of Life (HRQL) in Patients with Chronic Liver Diseases. Digestive Disease Week, Chicdago, Illinois, 2009.
124. Weinstein, A.A., Gerber, L., Moon, J., Kallman, J., Fang, Y., Winter, P., Moore, D., & Younossi, Z. (2010). Relationship between chronic sleep restriction and health-related quality of life. *Psychosomatic Medicine*, 72(3), A-123. American Psychosomatic Society 68th Annual Scientific Meeting, March 10 - 14, 2010, Portland
125. J Moon, J Kallman, Z Younoszai, Zahra, P Winter, Y Fang, L Gerber, ZM Younossi. Validation of Chronic Liver Disease-HCV Version (CLDQ-HCV) with Fatigue Severity Scale. Digestive Disease Week, Annual Meeting 2010, New Orleans, Louisiana.
126. Jillian B. Kallman, Patrice M. Winter, Juhi Moon, MaryEllen Earley, Lynn Gerber, Zobair M. Younossi. Determination of Relationships Between Objective and Self-Reports of Fatigue and Physical Performance in Subjects with Chronic Liver Disease. American Association for Study of Liver Disease 2010, Boston MA
127. Ali Weinstein, Jillian B. Kallman, Maria Stepanova, Brian P. Lam, Laura W. Poms, Fang Yun, Christopher Bach, Husam Alathari, Zobair M. Younossi. Prevalence and Independent Predictors of Psychiatric Conditions in Patients with Chronic Liver Disease (CLD). American Association for Study of Liver Disease 2010, Boston MA

Presentations Related to Outcomes and Health Services Research:

128. Z Younossi, J McHutchison. Is Norfloxacin for Spontaneous Bacterial Peritonitis Cost-Effective: An Economic Analysis. 46th Annual American Association for Study of Liver Disease Meeting. Chicago, IL. 1995. *Hepatology*, Vol. 22, Nov. 4, 166A, 1995.
129. C Teran, Z Younossi, W Carey. Cost-Effectiveness of Ultrasound-Guided Liver Biopsy for Diffuse Parenchymal Liver Disease. Digestive Disease Week Meeting. San Francisco, CA. *Gastroenterology*, Vol. 100 (No.4), A43, 1996.
130. A Aggarwal, J Ong, Z Younossi, A Arroliga, D Nelson, J Schafle, L Hoffman Hogg. Predictors of Survival and Resource Utilization in Patients with Liver Disease Admitted to Intensive Care Unit. American Association for Study of Liver Disease. Dallas, TX. 1999.
131. A Aggarwal, J Ong, D Nelson, J Schafle, L Hoffman Hogg, Z Younossi, A Arroliga. Prognostic Indicators in Patients with Chronic Liver Disease Admitted to the Medical Intensive Care Unit. American College of Chest Physicians. 1999.
132. S Bhatia, Z Younossi, N Boparai, J Henderson, B Parker. Factors Associated with Mortality in Acute Hepatic Failure. International Liver Transplantation Society. Berlin, Germany. June 2001. *Hepatology*, Vol.34 (No.4) Pt 2. 2001.
133. J Ong, L Martin, M Sheridan, R Collantes, P Nadkarni, Z Younossi. Health Insurance Status of Hepatitis C Virus-Positive Adult Persons in the United States. The American Public Health Association Meeting. 2003.
134. J.B. Kallman, N.L.H. Gerber, Y. Fang, C.H. Kim, R. Gupta, Z.M. Younossi. Demographic, Diagnostic and Disease Characteristics in Patients with Chronic Liver Disease that Correlate with Level of Physical Activity. American Academy of Physical Medicine & Rehabilitation 2008.
135. NL Gerber, J Kallman, CH Kim, R Gupta, ZM Younossi. Demographic, Diagnostic and Disease Characteristics in Patients with Chronic Liver Disease that Correlate with Level of Physical Activity. The American Academy of Physical Medicine and Rehabilitation. San Diego, CA, November. 2008
136. NL Gerber, J Kallman, I Kaur, Y Fang, ZM Younossi. Demographic, diagnostic and disease characteristics of patients with chronic liver disease correlates with physical activity. ISPRM Istanbul, Turkey, 2009
137. Nila Rafiq, Maria Stepanova, Hesham M. Mir, Ine-Mari Bornman, Brian Lam, Manirath Srishord, Zobair M. Younossi. Diabetes Related Mortality in Patients with Chronic Liver Disease. American Association for Study of Liver Disease 2009, Boston MA (Oral Presentation).
138. Jillian B. Kallman, Sang V. Tran, Aimal Arsalla, Dmitri Haddad, Maria Stepanova, Fang Yun, Valerie Wrobel, Manirath Srishord, Zobair M. Younossi. Screening for Hepatitis B (HBV) and Hepatitis C (HCV) in a Vietnamese Community of Northern Virginia. American Association For Study Of Liver Disease 2009, Boston MA.
139. C Gennings, R Agrawal, Y Fang, C Bach, B Lam, ZM Younossi. Stratification and Prediction of Outcomes of Bariatric Surgery Patients using the Relative Wellness Index (RWI). Digestive Disease Week, Annual Meeting 2010, New Orleans, Louisiana
140. Maria Stepanova, Hesham M. Mir, Noreen Hossain, Zobair M. Younossi. Diabetes Mellitus and Viral Hepatitis are Independent Predictors of Overall, Liver-Related and Hepatocellular Carcinoma-Related Mortalities in Hispanic Americans. AASLD 2010 Annual Meeting, Boston, MA

Presentations Related to Hepatitis C:

142. Z Younossi, D Bylund, L Wilkes, J McHutchison. Anti-LKM Antibody as a Predictor of Response to Alpha Interferon in Chronic Hepatitis C. #1280, *Hepatology*, 1994.
143. Z Younossi, I McHutchison. Interferon Treatment of Chronic Hepatitis C Infection: An Economic Analysis of Different Strategies. Digestive Disease Week Meeting. San Francisco, CA. 1996. *Gastroenterology*, Vol. 110 (No.4), A47, 1996.
144. G Cammell, K Easley, Z Younossi, W Carey. Predicting Cirrhosis without Liver Biopsy in Patients with Chronic Hepatitis C. Digestive Disease Week. Washington DC. *Gastroenterology*, Vol. 112(No.4), 1997.

145. G Cammell, Z Younossi, W Carey. The Utility of Liver Biopsy in Diagnosis of Hepatitis C. *Digestive Disease Week*. Washington, DC. Vol. 111(No.4), 1997.
146. Z Younossi, T Gramlich, M Goormastic, L Farquhar, M Westveer, P George, D Barnes, W Carey, J Mayes, D Vogt, JM Henderson. Hepatitis C (HCV) After Orthotopic Liver Transplantation. Recurrence vs. Rejection? *Digestive Disease Week*. Washington, DC. Vol. III,(No.4), 1997.
147. W Braun, Z Younossi. The Management of Hepatitis B and C in Twenty-Year Renal Transplant Recipients. Oral Presentation. American Society of Transplant Physicians. Chicago 1998.
148. Z Younossi, K Mullen, W Zakko, E Brandt, S Hodnick, M Kiwi, L Borzi, K Easley. Interferon 2b and Ribavirin vs. Interferon 2b and Amantadine for Chronic Hepatitis C (Nonresponder): A Multi-Center, Randomized, and Double-Blind Clinical Trial. American Association for Study of Liver Disease. Chicago 1998.
149. E Hadziyannis, Z Younossi, M Kiwi, S Hodnick C Starkey, B Yen-Lieberman. Comparison of Two PCR- Based Methods for Quantification of Hepatitis C RNA. American Association for Study of Liver Disease. Chicago 1998.
150. M O'Neil, Z Younossi, K Lee, M Kiwi, B Larive, L Calabrese. Epidemiology of Rheumatic Symptomatology in Patients Infected with Hepatitis C Virus. American College of Rheum. San Diego, CA 1998.
151. Z Younossi, M Singer, K Shermock, J McHutchison. The Role of Genotyping in Cost-Effectiveness of Interferon and Ribavirin for Chronic Hepatitis C. *Digestive Disease Week*, Orlando, FL. *Gastroenterology*, Vol. 166 (No.4): A1293, 1999.
152. IT Mayes, DP Vogt, JM Henderson, Z Younossi, D Barnes, WD Carey. Early Experience with Deliberate Cyclosporine Conversion for Recurrent Hepatitis C After Liver Transplantation. American Hepato-Pancreato-Biliary Congress. 1999.
153. J Ong, D Barnes, M Goormastic, B Yen-Lieberman, TL Gramlich, Z Younossi. Outcome of De Novo Hepatitis C in Heart Transplant Recipients of HCV-Antibody Positive Donors. *Digestive Disease Week*. Orlando, FL. *Gastroenterology*, Vol. 166 (No.4): A1259, 1999.
154. T Gramlich, J Ong, DS Barnes, M Goormastic, B Yen-Lieberman, Z Younossi. Pathologic Features of Hepatitis C in Heart Transplant Recipients. *Digestive Disease Week*, Orlando, FL. *Gastroenterology*, Vol. 116 (No.4): 1217, 1999.
155. Z Younossi, M Singer. Is Screening for Hepatitis C Cost-Effective? American Association for Study of Liver Disease. Dallas, TX. 1999.
156. M Singer, Z Younossi. Screening for Hepatitis C: Is it Cost Effective? Oral Presentation. Society for Medical Decision Making. 1999.
157. Z Younossi, K Mullen, W Zakko, E Brandt, S Hodnick D Barnes, W Carey, A McCullough, K Easley. Interferon 2b-Amantadine vs. Interferon Alpha-2b-Ribavirin Combination in Chronic Hepatitis C: Analysis of a Randomized Double-Blind Trial. American Association for Study of Liver Disease. Dallas, TX. 1999.
158. Z Younossi, N Dawson, E Stoller, S Wolfe. Lay Perceptions of Hepatitis C and Variation by Ethnic Origin. *Hepatology*, 1999.
159. D Vasillopoulos, Z Younossi, E Hadziyannis, N Boparai, T Gramlich, B Yen-Lieberman, E His, D Cook, E Ball, R Kimberly, L Calabrese. Patterns of Immune Activation in Hepatitis C Infection Associated With or Without Autoimmune Manifestations. American Association for Study of Liver Disease. Dallas, TX. 1999.
160. J Ong, N Boparai, C Speer, T Gramlich, M Kiwi, Z Younossi. Anxiety and Depression in Chronic Hepatitis C. American Association for Study of Liver Disease. Dallas, TX. 1999.
161. Z Younossi, K Mullen, S Hodnick M McCormick, D Bringman, D Barnes, WD Carey, AJ McCullough, K Easley. Triple Combination Therapy for Treatment of Chronic Hepatitis C. *Digestive Disease Week*. San Diego, CA. 2000.
162. Z Younossi, A McCullough, N Buchler, K Mullen, W Carey, D Barnes, B Donofrio. Induction vs. Standard Interferon Monotherapy for Patients with HCV Viremia and Normal ALT. *Digestive Disease Week*. San Diego, CA. 2000.

163. A DiBisceglie, S Schwartz, R Reddy, P Martin, G Gores, A Look, R Gash, D Van Thiel, Z Younossi, M Tong, T Hassanein, L Balart, J Fleckenstein, A Blei. Hepatitis C and Hepatocellular Carcinoma in African Americans. *Digestive Disease Week*. San Diego, CA. 2000.
164. D Vassilopoulos, Z Younossi, E Hadziyannis, N Boparai, T Gramlich, B Yen-Lieberman, E His, D Cook, E Ball, RP Kimberly. A Villa-Forte, LH Calabrese. Autoimmune Manifestations of Hepatitis C: Patterns of Immune Activation. *American Journal of Rheumatology*. 2000.
165. S Sarbah, Z Younossi, T Gramlich, A DiBisceglie, J Mayes, A Younoszai, M Goornastic. Hepatocellular Carcinoma, Hepatitis C and Ethnicity. *American Association for Study of Liver Disease*. Dallas, TX. 2000.
166. Z Younossi, KD Mullen, S Hodnick, D Barnes, W Carey, AJ McCullough, K Easley. Triple Combination of Interferon cx2b, Ribavirin and Amantadine for Hepatitis C Treatment Failures. *American Association for Study of Liver Disease*. Dallas, TX. 2000.
167. J Ong, Z Younossi. The Impact of Leukocyte Filtration during Orthotopic Liver Transplantation on HCV RNA Levels. *American Associate for the Study of Liver Diseases*. Dallas, TX 2001. *Hepatology*, Vol.34 (No.4) Pt 2. 2001.
168. J McHutchison, B Yoffe, R Brown, E Schiff, M Shiffman, R Carithers, T Wright, M Fried, R Gish, Z Younossi, N Poulivos. Preliminary Report of the Development of a Hepatitis C Web-Based Patient Registry at 11 U.S. Hepatology Units. *American Associate for the Study of Liver Diseases* 2001.
169. L Martin, K Irwin, Z Younossi. Development of a Hepatitis C-Specific Instrument for Monitoring Treatment Adherence. *Digestive Disease Week 2002*. San Francisco, CA. May 2002.
170. Z Younossi, A McCullough, D Barnes, A Post, J Ong, K Mullen, W Carey, R O'Shea, G Levinthal, T Gramlich, L Martin, D Bringman, A Tavill, D R Ferguson. Pegylated Interferon, Ribavirin and Amantadine for Treatment of Chronic Hepatitis C: A Multi-Center Clinical Trial. *American Association for Study of Liver Disease*. Boston, MA. 2002.
171. ZM Younossi, AJ McCullough, DS Barnes, A Post, JP Ong, KD Mullen, WD Carey, R O'Shea, G Levinthal, T Gramlich, L Martin, D Bringman, AS Tavill, DR Ferguson. Triple Combination of Pegylated Interferon Alpha 2b, Ribavirin and Amantadine for the Treatment of Chronic Hepatitis C. *Digestive Disease Week*. Orlando, FL. May 2003.
172. ZM Younossi, AJ McCullough, DS Barnes, A Post, JP Ong, KD Mullen, WD Carey, R O'Shea, G Levinthal, T Gramlich, L Martin, D Bringman, AS Tavill, DR Ferguson. Triple Combination of Pegylated Interferon Alpha 2b, Ribavirin and Amantadine for the Treatment of Chronic Hepatitis C. Schering Hepatitis Investigators' Network VII (SHINE). Huntington Beach, CA. February 2003.
173. Z Younossi, J Ong, R Collantes, J Assmann, R Sjogren, M Sjogren, D Farmer, L Martin. Darbepoetin Alfa (Da) for Ribavirin-Induced Anemia in Patients with Chronic Hepatitis C (CH-C) Treated with Pegylated Interferon and Ribavirin (PEG-IFN/RBV): A Preliminary Analysis. (Oral Presentation). *Digestive Disease Week*. New Orleans 2004.
174. Z Younossi, J Chan, K Schlauch, J Assmann, C Santini, J Ong, J Martin, T Gramlich, L McAllister S-Y Chang. Gene Expression Profiles of Patients with Chronic Hepatitis C (CH-C) Treated with Pegylated Interferon Alfa-2b and Ribavirin (PEG-IFN/RBV). *Digestive Disease Week*. 2004.
175. P Pockros, M Shiffman, E Schiff, N Afdhal, M Sulkowski, Z Younossi, T Wright, D Dieterich, J Jenkins, Gerhard J. Leitz, Peter J. Bowers. Long-Term Treatment with Epoetin Alfa Maintains Ribavirin Dose and Hemoglobin Levels in Anemic HCV-Infected Patients Receiving Interferon/Ribavirin (IFN/RBV) Therapy. *Digestive Disease Week*. 2004.
176. J Stamates, P Pockros, M Shiffman, E Schiff, N Afdhal, M Sulkowski, Z Younossi, T Wright, D Dieterich, J Jenkins, G Leitz, P Bowers Long-Term Treatment with Epoetin Alfa Maintains Ribavirin Dose and Hemoglobin Levels in Anemic HCV-Infected Patients Receiving Interferon/Ribavirin Therapy. 19th Annual Conference. *American Academy of Nurse Practitioners*. 2004.
177. Z Younossi, J Chan, K Schlauch, R Collantes, J Assmann, C Santini, J Ong, J Martin, L Mc Allister, SY Chang. Gene Expression Profiles of Patients with Chronic Hepatitis C Developing Treatment-Related Anemia. *Association for Study of Liver Disease*. Boston, MA. October 2004.

178. D Farmer, R Collantes, S Makay, JP Ong, H Gujral, L Farquhar, ML Carniello, R Sjogren, ZM Younossi. Filgrastim for the Neutropenia Associated with Combination Therapy in Chronic Hepatitis C. Digestive Disease Week 2005.
179. T Schiano, M Charlton, Z Younossi, E Galun, Timothy Pruett, Ran Tur-Kasa, Rachel Eren, S Dagn. N Graham, and J Andrew. A Phase I/II Study of Monoclonal Antibody HCV-ABXTL-68 in Patients Requiring Liver Transplant for HCV. Association for Study of Liver Disease, San Francisco 2005.
180. L Ramsey, F Nader, CH Bai, , H Gujral, K Terra, S McKay, R Collantes, JP Ong, R Sjogren, ZM. Younossi. Darbepoetin Alfa (DA) and Filgrastim (FL) for the Management of Anemia and Neutropenia of Antiviral Therapy for Chronic Hepatitis C. IDSA Meeting, Toronto, Canada 2006
181. F Nader, CH Bai, K Terra, C Gurung, M Srishord, R Collantes, JP Ong, R Sjogren, ZM Younossi. The Use of Growth Factors (GF) in the Re-treatment of Patients with Chronic Hepatitis C (CHC) Who Are Previous Non Responders to Combination Therapy. EASL, Barcelona. 2007.
182. F Nader, CH Bai, K Terra, C Gurung, M Srishord, R Collantes, J Ong, M Sjogren, R Sjogren, ZM Younossi Darbepoetin Alfa (DA) and Filgrastim (FA) for the Management of Anemia and Neutropenia in Chronic Hepatitis C (CH-C) Digestive Disease Week. Washington, D.C. 2007.
183. ZM Younossi, R Collantes, A Baranova, A Kim, G Manyam, M Stepanova, C Santini, C Sigua, J Chan, A Iverson, SY Chang. Gene Expression Biomarkers Predicting Response to Pegylated Interferon alpha (PEG-IFN) and Ribavirin (RBV) in the Preipheral Blood of Patients with Chronic Hepatitis C (CH-C), Non-responder (NR) to Previous Treatment. American Association for Study of Liver Disease. Boston, MA, 2007.
184. Z Younossi, R Collantes, A Baranova, A Bakshi, M Stepanova, G Manyam, C Santini, C Sigua, J Chan, A Iverson, SY Chang. Gene Expression Biomarkers Predicting Response to Pegylated Interferon Alpha (PEG-IFN) and Rivavirin (RBV) in Treatment-Naive Patients with Chronic Hepatitis C (CH-C). American Association for Study of Liver Disease, Boston, MA, 2007.
185. Z Younossi, A Baranova, R Collantes, M Stepanova, M Garone Jr., A Arsalla, SAHmad, C Santini, C Sigua, J Chan, BS, A Iverson, SP. Chang. Gene Expression Biomarkers Can Predict Sustained Virologic Response (SVR) Early After Initiation of Pegylated Interferon Alfa (PEG-IFN) And Ribavirin (RBV) In Patients With Genotype 1 Chronic Hepatitis C (Oral Presentation, Plenary Session). American College of Gastroenterology, Philadelphia, PA, 2007
186. Z Younossi, A Baranova, M Stepanova, A Afendy, A Wheeler, N Hossain, A Bakshi, C Santini, C Sigua, J Chan, A Iverson, S Chang. A Panel of Gene Expression Biomarkers Predicting Sustained Virologic Response (SVR) in Chronic Hepatitis C Patients (CH-C) Treated with Pegylated Interferon Alpha and Ribavirin. European Association for the Study of Liver, Milan, Italy 2008.
187. Z Younossi, A Baranova, A Afendy, M Stepanova, S Schmidt, I Younossi, F Nader, C Santini, J Chan, SY Chang. Gene Expression Associated with Advanced Fibrosis in Patients with Chronic Hepatitis C (CH-C). European Association for the Study of Liver, Milan, Italy 2008.
188. A Afendy, M Stepanova, A Baranova, N Hossain, I Younossi, A Wheeler, ZM Younossi. Differential Gene Expression between Caucasian and African American Patients With Chronic Hepatitis C. American Association For Study Of Liver Disease. San Francisco, CA 2008
189. E. Lawitz, Z.M. Younossi, M. Shiffman, S. Gordon, R. Ghalib, W. Long, A. Muir, J. McHutchison. Randomized Trial Comparing Systemic And Local Reactions To Controlled-Release Interferon Alpha2b And Pegylated-Interferon Alpha2b In Hepatitis C Patients Who Failed Prior Treatment. European Association for the Study of Liver, Copenhagen, Denmark 2009
190. A Birerdinc, A Afendy, M Stepanova, I Younossi, G Manyam, A Baranova, ZM. Younossi. Functional Pathway Analysis of Genes Associated with Response to Treatment in Chronic Hepatitis C (CH-C). American Association for the Study of Liver Diseases' (AASLD) The Henry M. and Lillian Stratton Basic Research Single Topic Conference 2009, Atlanta, GA
191. E. Lawitz, Z.M. Younossi, P. Mehri, A. Rigney, Z. Krastev, K. Tchernev, D. Takov, W. A. Long. Early Viral Response Of Controlled-Release Interferon Alpha2b And Ribavirin Vs. Pegylated-Interferon Alpha2b And Ribavirin In Treatment-Naïve Genotype1 Hepatitis C: 12 Week Results

- (Select-2 Trial). European Association for the Study of Liver Disease Meeting 45th Annual Meeting 2010, Vienna, Austria
192. W.A. Long, D. Takov, K. Tchernev, I. Kotzev, A. Rigney, Z. Krastev, S. Stoyanov, R. Balabanska, E. Lawitz, Z. Younossi, R. Ghalib, E. Zuckerman, R. Safadi, R. Tur-Kaspa, N. Assy, Y. Lurie. Q2week Controlled-Release-Interferon-Alpha2b+Ribavirin Reduces Flu-Like Symptoms >50% And Provides Equivalent Efficacy In Comparison To Weekly Pegylated-Interferon-Alpha2b+Ribavirin In Treatment-Naïve-Genotype-1-Chronic-Hepatitis-C: Results From Empower, A Randomized-Open-Label-12-Week-Comparison In 133 Patients. (Late Breaker). European Association for the Study of Liver Disease Meeting 45th Annual Meeting 2010, Vienna, Austria
 193. Z. Younossi, D Limongi, M Stepanova, M Pierobon, A Afendy, L. Liotta, E. Petricoin. Protein Pathway Biomarkers Predicting Sustained Virologic Response (SVR) to Pegylated Interferon (PEG-IFN) and Ribavirin (RBV) in Patients with Chronic Hepatitis C (CH-C). European Association for the Study of Liver Disease, 45th Annual Meeting 2010, Vienna, Austria.
 194. G Manyam, I Younossi, T Gramlich, A Baranova, Z Younossi, A Birerdinc, M Stepanova, A Afendy. Up-regulation of Matrix Metalloproteinase 9 (MMP-9) and Interleukin-8 (IL-8) in African-American Patients with Chronic Hepatitis C. Digestive Disease Week, Annual Meeting 2010, New Orleans, Louisiana
 195. D Limongi, M Stepanova, A Afendy, M Pierobon, R Agrawal, L Liotta, E Petricoin, ZM Younossi. Protein Pathway Biomarkers Predicting Sustained Virologic Response (SVR) to Pegylated Interferon (PEG-IFN) and Ribavirin (RBV) in Treatment-Naive Genotype 1 Patients with Chronic Hepatitis C. (Oral Presentation, Plenary Session) Digestive Disease Week, Annual Meeting 2010, New Orleans, Louisiana. D Desai, M Estep, A Birerdinc, H Mir, A Baranova, V Chandhoke, ZM Younossi. Markers of Insulin Resistance in During HCV Treatment: A Relationship to Sustained Virologic Response (SVR). Digestive Disease Week, Annual Meeting 2010, New Orleans, Louisiana
 196. A Birerdinc, M Stepanova, A Afendy, G Manyam, I Younossi, T Gramlich, A Baranova, ZM Younossi. Up-Regulation of Matrix Metalloproteinase 9 (MMP-9) and Interleukin-8 (IL-8) in African-Americans Patients with Chronic Hepatitis C. (Poster with Distinction) Digestive Disease Week, Annual Meeting 2010, New Orleans, Louisiana.
 197. Aybike Birerdinc, Arian Afendy, Maria Stepanova, Issah Younossi, Ancha Baranova, Zobair M. Younossi. Baseline Gene Expression Profile Associated with Development of Mild and Severe Anemia During Treatment of Chronic Hepatitis C (CH-C) Patients with Pegylated interferon and Ribavirin (PEG-IFN+RBV). American Association for Study of Liver Disease 2010, Boston MA
 198. Aybike Birerdinc, Arian Afendy, Maria Stepanova, Issah Younossi, Ancha Baranova, Zobair M. Younossi. Gene Expression Profiles Associated with Depression in Patients with Chronic Hepatitis C (CH-C). American Association for Study of Liver Disease 2010, Boston MA (Oral Presentation)
 199. Aybike Birerdinc, Maria Stepanova, Dolores Limongi, Arian Afendy, Mariaelena Pierobon, Issah Younossi, Lance Liotta, Ancha Baranova, Emanuel F. Petricoin, Zobair M. Younossi. AKT Activation is Associated with Sustained Virologic Response (SVR) After Treatment with Pegylated Interferon-alfa and Ribavirin (PEG-IFN+RBV) in Patients with Chronic Hepatitis C (CH-C). American Association for Study of Liver Disease 2010, Boston MA
 200. Walker A. Long, Eric Lawitz, Yoav Lurie, Zahary Krastev, Dimitar Takov, Konstantin G. Tchernev, Amy Rigney, Nimer Assy, Zobair M. Younossi. Adverse Event Reporting During HCV Treatment Via Weekly Clinic Visits Substantially Underestimates Flu Frequency & Severity Compared To Daily ePRO: Results From 133 Patients In EMPOWER. American Association for Study of Liver Disease 2010, Boston MA (Late Breaker). American Association for Study of Liver Disease 2010, Boston MA

Presentations Related to Other Liver Diseases:

201. S Hitchcock-De Gregory, Z Younossi, W Brown. Serum Albumin Binds to Tropomyosin. Biophys Journal 47:510a, 1985.

202. L Miller, M Kalnoski, Z Younossi, J Buliniski, E Reisler. Antibodies Directed Against the N Terminus of Actin Bind to the Acto-S-1 Complex. *Biophys*, 151:392a, 1987.
203. M Poleski, Z Younossi, D Cloutier, D Collins. Prevalence of Ulcerative Colitis and Crohn's Disease in Family Members of 254 Inflammatory Bowel Disease. Patients Comparison Between Those Born in High and Low Risk Areas. Trends in Inflammatory Bowel Disease Meeting. Victoria, Canada. April 6-9, 1994.
204. Z Younossi, V Rodgers, E Beutler, A Johnson. 2-Chlorodeoxyadenosine (Cladribine) Treatment of Refractory Crohn's Disease: A Pilot Study. 10th World Congresses of Gastroenterology. Los Angeles, CA. October 1994.
205. Z Younossi, D Collins, D Cloutier, M Poleski. Inflammatory Bowel Disease in Migrants from Low-Risk Area to Montreal, Canada: A Comparison between Age of Onset of Ulcerative Colitis and Crohn 's Disease. 10th World Congresses of Gastroenterology. Los Angeles, CA. 1994.
206. Z Younossi, D Collins, D Cloutier, M Poleski. Inflammatory Bowel Disease in Montreal, Canada: Comparison between High-Risk and Low-Risk Area. 10th World Congresses of Gastroenterology. Los Angeles, CA. 1994.
207. Z Younossi, W Strum, P Teirstein, R Schatz. Upper GI Bleeding in Postcoronary Stent Patients Following Aspirin and Anticoagulant Treatment. Oral Presentation at Digestive Disease Week Meeting. San Diego, CA. May 14-17, 1995.
208. Z Younossi, JG McHutchison, A Sedghi-Vaziri, CN Broussard. Changes in the Serum-Ascites Albumin Gradient Following Transjugular Intrahepatic Porto-Systemic Shunt. American Association for Study of Liver Disease Meeting. Chicago, IL. 1996). *Hepatology*, Vol. 24 (No.4), 446A, 1996.
209. P Pockros, Z Younossi, A Saven. An Open-Label Pilot Study of 2-Chlorodeoxyadenosine (CdA) in the Treatment of Early Stage Primary Sclerosing Cholangitis (PSC). 4 7th Annual American Association for Study of Liver Disease Meeting. Chicago, IL. 1996). *Hepatology*, Vol. 24 (No.4), 170A, 1996.
210. J Dumot, D Barnes, Z Younossi, J Henderson, W Carey. Efficacy of Hepatitis A Vaccine in Patients with End-Stage Liver Disease and After Liver Transplantation. *Digestive Disease Week*. Washington, DC. Vol.III(No.4), 1997.
211. R Gacad, Z Younossi, N Boparai, J Hale, WD Carey. Learning Ultrasound-Guided Liver Biopsy. *American College of Gastroenterology*, 1997.
212. M Hang, M Ishitani, W Carey, D Barnes, Z Younossi, J Mayes, D Vogt, M Henderson. Two Compartmental HBIG Pharmacokinetics Allows for Prolonged Outpatient Dose Intervals Following OLT for Chronic HBV. *American Society of Transplant Physicians*. Chicago 1998.
213. M Haug, M Ishitani, S Wimberley, W Carey, D Barnes, Z Younossi, J Mayes, JM Henderson, D Vogt. Hepatitis B Immune Globulin (HBIG) Disposition after Liver Transplant. *American Hepato-Pancreato-Biliary Congress*. 1999.
214. A Aggarwal, J Ong, D Nelson, J Schafle, L. Hoffman Hogg, Z Younossi, A Arroliga. Predictors of Mortality in Patients with Liver Disease Admitted to the Medical Intensive Care Unit. Oral Presentation. *American College of Chest Physicians*. 1999.
215. B Parker, P Potter, V Sabharwal, Z Younossi, D Vogt, J Mayes, JM Henderson. Intraoperative Leukocyte Reduction and The Incidence of Acute Cellular Rejection after Orthotopic Liver Transplantation. *International Liver Transplant Society (ILTS) Meeting*. 2000.
216. Z Younossi, S Sarbah, A Di Bisceglie, T Gramlich, P Osmack, A Younoszai, L Grosso, J Cooper, D Duncan, R Seneca. Determination of HFE Mutations in the Paraffin-Embedded Liver Biopsy Blocks of Patients with Hepatocellular Carcinoma. *American Associate for the Study of Liver Diseases*. Dallas, TX 2001. *Hepatology*, Vol. 34 (No.4) Pt 2. 2001.
217. E Galun, Z Younossi, et al. A Phase 2 Clinical Study Evaluating Safety and Efficacy of Hepex-B, A Mixture of Two Human Monoclonal Antibodies to HBsAg in Combination with Lamivudine in Chronic HBV Patients. *Association for Study of Liver Disease*. Boston, MA. October 2003.

218. S Srivastava, M Duncan, A Joseph, J Ong, D Duncan, Z Younossi. Budd-Chiari Syndrome (BCS) with Mesenteric Vein Thrombosis (MVT) Treated by Direct Intrahepatic Portocaval Shunt (DIPS) and Mechanical Thrombectomy. 68th Annual Scientific Meeting. American College of Gastroenterology, Baltimore, MD. 2003.
219. J Estep, L O' Reilly, G Grant, K Schlauch, J Ong, J Piper, J Jonsson, V Chandhoke, K Smith, Z Younossi. Gene Expression Profile Associated With Activated Hepatic Stellate Cells: Implications for Hepatic Fibrosis. Digestive Disease Week. 2004.
220. J Michael Estep, G Grant, L O' Reilly, J Piper, J Jonsson, M Gupta, JP Ong, V Chandhoke, ZM Younossi. Expression Of Genes Associated With Apoptosis Of The Hepatic Stellate Cells Obtained From The Explanted Livers. American Transplant Congress/American Society of Transplantation, Seattle, WA. 2005.
221. Z Younossi. New Techniques Redefine Assessment of Liver Disease. Digestive Disease Week. Washington, DC, 2007.
222. Z Younossi, Y. Benhamou, E. Gane, S. Zeuzem, J. Heathcote, P. Marcellin, J. Sorbel, K. Borroto-Esoda, F. Rousseau and A. Snow-Lampart. Lack of Influence of Baseline Genotype on Antiviral Response In Subjects With Chronic Hepatitis B Infection Receiving Tenofovir DF 300 MG QD For 1 Year. Digestive Disease Week. San Diego, CA, 2008.
223. SS Lee, EJ Heathcote, W Sievert, H Trinh, K Kaita, ZM Younossi, J George, M Shiffman, P Marcellin, J Sorbel, J Anderson, E Mondou, J Quinn, Franck Rousseau. Tenofovir Disoproxil Fumarate (TDF) Versus Adefovir Dipivoxil (ADV) In Asians With HBeAg-Positive And HBeAb-Negative Chronic Hepatitis B Participating In Studies 102 And 103. American Association For Study Of Liver Disease. San Francisco, CA 2008
224. SS Lee, EJ Heathcote, W Sievert, H Trinh, K Kaita, ZM Younossi, J George, M Shiffman, P Marcellin, J Sorbel, J Anderson, E Mondou, J Quinn, Franck Rousseau. Tenofovir Disoproxil Fumarate (TDF) Versus Adefovir Dipivoxil (ADV) In Asians With HBeAg-Positive And HBeAb-Negative Chronic Hepatitis B Participating In Studies 102 And 103. The 13th International Symposium on Viral Hepatitis and Liver Disease (ISVHLD) 2009
225. Rubin Aquino, Maria Stepanova, Abdullellah Alsheddi, Ravindra Gupta, Fang Yun, Zobair M. Younossi. Independent Predictors of Fibrosis in Patients with Chronic Liver Disease. American Association For Study Of Liver Disease 2009, Boston MA
226. S Lee, Jacobs, Z Younossi, E Mandoux. Three Years Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Asians with HBeAg-positive and HBeAg-negative Chronic Hepatitis B, Preliminary Analysis. American Association for Study of Liver Disease 2009, Boston MA.
227. Ed Gane, S. Lee, J Heathcote, W Sievert, H Trinh, K Kaita, Z Younossi, J George, P Marcellin, D Coombs, Jane Anderson, Elsa Mondou. Four Years Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Asians with HBeAg-positive and HBeAg-negative Chronic Hepatitis B (CHB), Preliminary Analysis. American Association for Study of Liver Disease 2010, Boston MA.
228. Mitchell L Shiffman, Gadi Lalazar, Adrian Reuben, Stuart Gordon, Arthur McCullough, Rajender Reddy, Fred Poordad, Zobair Younossi, John Vierling, Alexander Fich, Elimelech Zuckerman, Scott Friedman, Rifaat Safadi, Yaron Ilan, Arun Sanyal. Assessment Of Cirrhosis By A Non-Invasive ¹³c-Methacetin Breath Test: Results of A Phase 3 Multicenter Trial. American Association for Study of Liver Disease 2010, Boston MA
229. Ed Gane, Samuel S. Lee, E. Jenny Heathcote, William Sievert, Huy Trinh, Kelly Kaita, Zobair Younossi, Jacob George, Patrick Marcellin, Derek Coombs, Jane Anderson, Elsa Mondou. Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Asians with HBeAg-positive and HBeAg-negative Chronic Hepatitis B (CHB), Four Year Preliminary Analysis. Submitted to Asian Pacific Study of Liver Disease (APASL 2011).

LECTURES AND FACULTY PRESENTATIONS

Lectures Related to Non-Alcoholic Fatty Liver Disease and Obesity:

1. Non-Alcoholic Fatty Liver Disease. Grand Round. Cleveland Clinic. Ft Lauderdale, FL. June 1999.
2. Non-Alcoholic Fatty Liver Disease. Cleveland Clinic Medical Grand Round. Cleveland, OH. June 1999.
3. The Spectrum of Fatty Liver Disease. 36th Annual Cleveland Clinic Gastroenterology Update. Cleveland, OH. September 1999.
4. Non-Alcoholic Fatty Liver Disease: A Review. Department of Endocrinology Grand Round. The Cleveland Clinic Foundation. Cleveland, OH. October 1999.
5. Non-Alcoholic Fatty Liver Disease. American Association for the Study of Liver Disease Regional Course. Chicago, IL. March 2000.
6. Hepatitis B, Non-alcoholic Steatohepatitis and Hemochromatosis. South Point Hospital. Cleveland, OH. May 2000.
7. Non-Alcoholic Steatohepatitis. Frontiers in Gastroenterology. Case Western Reserve University. Cleveland, OH. May 2000.
8. Non-Alcoholic Steatohepatitis. American College of Gastroenterology Post-Graduate Course. New York, NY. October 2000.
9. Pathogenesis of Non-alcoholic Steatohepatitis. American College of Gastroenterology. Early Breakfast Symposium on Non-alcoholic Steatohepatitis. New York, NY. October 2000.
10. Clinical Trial on Non-alcoholic Steatohepatitis. American Association for the Study of Liver Disease. Early Morning Breakfast Session. Dallas, TX. October 2000.
11. Basic Research in Non-alcoholic Steatohepatitis. American Association for the Study of Liver Disease. Early Morning Breakfast Session. Dallas, TX. October 2000.
12. Non-Alcoholic Steatohepatitis. SHINE Investigator Meeting. Orlando, FL. February 2001.
13. Hepatitis C and Steatosis. SHINE Investigator Meeting. Orlando, FL. February 2001.
14. Non-Alcoholic Steatohepatitis. American Association for the Study of Liver Disease. Clinical Update in Hepatology. March 2001.
15. Non-Alcoholic Steatohepatitis Update. Clark Society. Washington, DC. February 2001
16. Non-alcoholic Steatohepatitis Update. Walter Reed Army Medical Center. Gastroenterology Grand Rounds. April 2001.
17. Clinical Aspects of Non-Alcoholic Fatty Liver Disease. Symposium on Obesity and Liver Disease. Digestive Disease Week. May 2001.
18. The Epidemiologic and Economic Impacts of Non-Alcoholic Fatty Liver Disease in the United States. American Association for the Study of Liver Disease Workshop. Digestive Disease Week. May 2001.
19. Non-alcoholic Steatohepatitis Oral Presentations: Co-Moderator. Digestive Disease Week. May 2001.
20. Non-alcoholic Steatohepatitis Update. Georgetown University. Washington, DC. June 6, 2001.
21. Update on Non-alcoholic Steatohepatitis: Maryland GI Society. October 2001.
22. An Update on Non-alcoholic Steatohepatitis. Medical Grand Rounds. Inova Fairfax Hospital. January 2002.
23. Non-alcoholic Steatohepatitis and Hepatitis C: Cornell University. January 2002.
24. HCV & Steatosis: SHINE Investigator Meeting. February 2002.
25. An Update on Fatty Liver Disease: CMD Dinner Program. Cleveland, OH. April 2002.
26. Non-alcoholic Steatohepatitis: CME Dinner Program. Columbus, OH. April 2002.
27. Natural History of Non-alcoholic Steatohepatitis. Digestive Diseases Week. San Francisco, CA. May 2002.
28. Non-Alcoholic Fatty Liver Disease. Rochester. NY 2002.
29. Spectrum of Fatty Liver Disease. Non-alcoholic Steatohepatitis Non-Alcoholic Steatohepatitis. American Association for the Study of Liver Diseases. Single Topic Conference. September 2002.

30. Non-Alcoholic Steatohepatitis. Non-alcoholic Steatohepatitis Medical Grand Rounds. Arlington Hospital. October 2002.
31. Obesity-Related Fatty Liver. Meet the Experts Conference. Inova Fairfax Hospital. December 2002.
32. Non-Alcoholic Fatty Liver Disease. Pittsburgh Gastroenterologists. February 2003.
33. Spectrum of Non-Alcoholic Fatty Liver Disease. SHINE Investigator Meeting. Los Angeles, CA. February 2003.
34. Non-Alcoholic Steatohepatitis. Maryland GI Society. Bethesda, MD. March 2003.
35. Non-Alcoholic Steatohepatitis. Baltimore Gastroenterologists. Baltimore, MD. June 2003.
36. The Spectrum of Non-Alcoholic Fatty Liver Disease. Medical Grand Round. The George Washington University. April 2004.
37. Non-Alcoholic Fatty Liver Disease and the Epidemic of Obesity. Transplant Grand Round. Inova Fairfax Round. June 2004.
38. Non-Alcoholic Fatty Liver Disease. Axcan National Meeting. Washington DC. July 2004.
39. Non-Alcoholic Fatty Liver Disease: Management American Association for Study of Liver Diseases. Post Graduate Course. Boston, MA. 2004.
40. Non-Alcoholic Fatty Liver Disease: What to Do with Your Fatty Liver Patients. American College of Gastroenterology. Orlando, FL. 2004.
41. Management of Non-Alcoholic Fatty Liver Disease: Medical Grand Rounds at Salem Veterans Affairs, Roanok, VA, 2004.
42. Non-Alcoholic Fatty Liver Disease. Rochester, NY. 2004.
43. Interaction between Non-alcoholic Fatty Liver Disease and Hepatitis C. Asian Pacific Association for the Study of the Liver. New Delhi, India. 2004.
44. Insulin Resistance and Non-alcoholic Fatty Liver Disease. Asian Pacific Association for the Study of the Liver. New Delhi, India. 2004.
45. The Spectrum of Non-alcoholic Fatty Liver Disease. Post Graduate Institute, Chandigarh, India, 2004.
46. Obesity-related Non-alcoholic Fatty Liver Disease. Thomas Jefferson University, GI Grand Round. 2005
47. Non-alcoholic Steatohepatitis. Washington VA Hospital, GI Conference, 2005
48. Management of Non-alcoholic Fatty Liver Diseases. Walter Reed and American College of Gastroenterology Bi-annual GI course, McLean, VA. 2005.
49. Epidemiology of Non-alcoholic Fatty Liver Disease in Bariatric Surgery Patients. Digestive Disease Week, Chicago, IL. 2005.
50. Adipokines in Non-alcoholic Fatty Liver Diseases. 7th International Conference on Cytokines and Chemokines. Montreal, CA. 2005.
51. Translational Research, Mid-Atlantic Biotechnology Conference, Washington D.C. Translational Research 2005.
52. Natural History of Non-alcoholic Steatohepatitis. American College of Gastroenterology. Honolulu, HI. 2005.
53. Non-alcoholic Steatohepatitis. American College of Physicians Meeting Washington DC 2005
54. Non-alcoholic Fatty Liver Disease Grand Round, University of California, Sacramento, CA. 2005.
55. Epidemiology and Natural History of Non-alcoholic Steatohepatitis. University of Pittsburgh GI/Hepatology Course, Pittsburgh, PA. 2005.
56. Obesity and Liver Disease 16th Annual AMOAA Meeting, Reston, VA. 2005.
57. HCV, Steatosis and Metabolic Syndrome. Postgraduate Institute of Medicine, Scottsdale, AZ. 2006.
58. Epidemiology, Natural History and Progression of Non-alcoholic Fatty Liver Disease. Non-alcoholic Steatohepatitis Expert Panel Meeting. Vienna, Austria. 2006
59. Translational Research Using Genomics and Proteomics to Study Human Diseases. Inaugural Speaker, The President's Series, Inova Health System 2006.

60. Non-alcoholic Steatohepatitis, Basic Science Oral Presentation (Co-Chair). American Association for the Study of Liver Disease, Boston, MA. 2006
61. Proteomics. Early Morning Session (Faculty). American Association for the Study of Liver Disease, Boston, MA. 2006.
62. The Role of Hepatic Steatosis in other Liver Diseases. Post graduate course of American Association for the Study of Liver Disease. Boston, MA. 2007.
63. From Bench to Bedside in Liver Disease. American College of Physicians, Virginia Chapter, Tyson's Corner, VA. 2007
64. Metabolic Syndrome and Liver Disease: Pre & Post Liver Transplantation. American Transplant Congress. San Francisco, CA. 2007.
65. Hepatic Steatosis as a Risk Factor in the Progression of Viral Hepatitis. Canadian Laboratory Medicine Congress. Toronto, Canada. 2007.
66. Non-alcoholic Fatty Liver Disease. Annual Hepatology Roundup. Baylor University Medical Center. Huston, Texas. 2007.
67. Fatty Liver Disease. American Liver Foundation. Chicago, Il. 2007.
68. Proteomics. Meet the Professor Session. American Association for the Study of Liver Disease. Boston, MA, 2007.
69. Epidemiology of Non-Alcoholic Fatty Liver Disease. Early Breakfast Session, American Association for the Study of Liver Diseases, Boston, MA, 2007.
70. The impact of Steatosis, Insulin Resistance and Metabolic Syndrome on HCV Treatment. Hepatitis C Metabolic Advisory Board. New York, December 2007
71. The Evaluation and Management of Non-alcoholic Fatty Liver Disease. Medical Grand Round, Inova Fairfax Hospital, December 2007
72. Non-alcoholic Steatohepatitis Advisory Board, Chair. Boston, MA February 2008
73. Metabolic Syndrome. Chronic Liver Disease Foundation, CME Program, Las Vegas, NV. March 2008
74. Non-alcoholic Fatty Liver Disease: From Clinical Management to Liver Transplantation"? Piedmont Hospital's Updates on Liver and Kidney Disease and Transplantation Course. Atlanta, GA, April 2008
75. Non-alcoholic Steatohepatitis and Fatty Liver. Scripps Clinic's 23rd Annual New Treatments in Chronic Liver Disease, La Jolla, CA, April 2008.
76. Epidemiology of NAFLD. NAFLD Advisory Board, Milan, Italy, April 2008
77. Drugs should be used for Non-alcoholic Steatohepatitis. AASLD Clinical Symposium on "Drug Therapy for Non-alcoholic Fatty Liver Disease". Digestive Disease Week 2008, San Diego, California, May 2008
78. State-of-the-Art lecture for Digestive Disease Week Annual Meeting 2008. "Non-alcoholic Fatty Liver Disease - Does it need to be Treated?" San Diego California, May 2008.
79. Non-alcoholic Fatty Liver Disease. Middlesex Hospital Symposium. Middletown, Connecticut, May 2008
80. Dermatology and Metabolic Syndrome. Multidisciplinary-Multispecialty Round Table of Experts During International Psoriasis Council Meeting, Dallas, Texas September 2008
81. Fatty Liver Disease. "Sixth Annual Duke Liver Disease Update and Symposium", Durham, North Carolina, September 2008
82. Recent Advances and Emerging Therapies in Chronic Liver Disease: Fatty Liver Disease. "9th Annual International Hot Topics in Liver Conference". Saint Luke's Hospital. Houston, Texas. October 2008
83. Current Treatment of Non-alcoholic Fatty Liver Disease. Symposium on NAFLD. Medica Sur Clinic and Foundation. Mexico City, Mexico. October 2008
84. Prognosis and Treatment of NASH in the Liver and Beyond: Lifestyle or Pharmacology? Post-graduate Course, Meet-the Professor Session, American Association for the Study of Liver Disease. San Francisco, California 2008

85. Obesity-related Liver Disease: Non-alcoholic Fatty Liver Disease (Grand Round): Albert Einstein College of Medicine-Montefiore Medical Center. New York, NY. November 2008
86. Non-alcoholic Fatty Liver Research. Mount Sinai School of Medicine Liver Research Seminar. January 2009
87. Natural history and clinical evaluation of NAFLD and NASH. “8th International Meeting on Therapy in Liver Diseases”, Barcelona, Spain September 2009
88. Update in the Treatment for Non-alcoholic Fatty Liver Disease (NAFLD). General Hepatology Update Course, American Association for the Study of Liver Disease, Boston, MA, November 2009
89. Diagnosing NAFLD/NASH: Who to Screen and How to Confirm the Diagnosis? UEGW/WCOG GASTRO 2009, London, United Kingdom, November 2009
90. Non-alcoholic Fatty Liver Disease. Carolinas Medical Center-CME Liver Course, Charlotte, NC, December 2009.
91. Hepatic Encephalopathy-CME, Chronic Liver Disease Foundation, Las Vegas, NV January 2010
92. NAFLD and NASH. Scripps Clinic 25th Annual Treatment in Chronic Liver Disease March 2010
93. Controversy: Results from PIVENS Trial (IR is not Important). Scripps Clinic 25th Annual Treatment in Chronic Liver Disease, March 2010
94. NASH: Noninvasive Markers – Emerging Alternatives to Biopsy: Measuring steatosis, fibrosis and cell death. Symposium: What’s New and Hot in Clinical Hepatology. Digestive Disease Week 2010, New Orleans, LA, May 2010
95. Non-Alcoholic Fatty Liver Disease: When should I biopsy? How should I treat? American College of Gastroenterology Annual Meeting, Post Graduate Course 2010, San Antonio, Texas, October 2010.
96. The Role of Liver Biopsy in the Future Management of NAFLD. Early Breakfast Session, American College of Gastroenterology Annual Meeting, San Antonio, Texas, October 2010.

Lectures Related to Quality of Life Research:

97. Health-Related Quality of Life and Chronic Liver Diseases. Case Western Reserve University. Cleveland, Ohio. March 1999.
98. Health-Related Quality of Life in Clinical Research of Encephalopathy. 10th International Symposium on Hepatic Encephalopathy. Istanbul Turkey. May 1999.
99. Health Policy and Research. Co-Moderator Oral Presentation. American Association for the Study of Liver Disease Meeting. Dallas, TX. November 1999.
100. Economic and Quality of Life Outcomes for Viral Hepatitis. Bluegrass Symposium on Chronic Viral Hepatitis. University of Kentucky. Lexington, KY. October 1999.
101. Quality of Life and Symptom Assessment in Hepatitis C. Lunch Breakout Session American Association for the Study of Liver Disease, Post-Graduate Course. Dallas, TX. October 2000.
102. Health-Related Quality of Life and Liver Transplantation. Transplant Grand Rounds UCLA. December 2001.
103. Quality of Life in Chronic Liver Disease: The Impact of Treatment and Liver Transplantation. The 8th Annual Virginia Liver Symposium. VCU, Richmond, VA. March 2004.
104. Makes a Difference: Improving Outcomes and Quality of Life in Patients With Hepatitis C. Orlando, FL. 2004.
105. Health-related Quality of Life and Liver Transplantation. American Transplant Congress Meeting, Seattle, WA. 2005
106. Health-related Quality of Life in Hepatitis C. Indenix Presentation. Cambridge, MA. 2005
107. Health Related Quality of Life in Hepatitis C: Expert Panel Meeting on Extra Hepatic Burden of HCV Infection. New York, NY, December 2007
108. Quality of Life Assessment in HCV, Merck Headquarters. December 2007
109. Quality of Life in Chronic Liver Disease, Chairperson for the Session. UEGW/WCOG GASTRO 2009, London, United Kingdom, November 2009

Lectures Related to Outcomes and Health Services Research:

110. A Cost Effective Evaluation of Patients with Elevated Liver Enzymes. 33rd Annual Cleveland Clinic Foundation, Gastroenterology Update. Cleveland, Ohio. November 1996.
111. Understanding Evidence-Based Medicine. Course Director. The Clinic Foundation. Cleveland, Ohio. March 1999.
112. Methodologies in Healthcare Outcomes in Gastroenterology: AGAGRC San Diego, CA. December 1999.
113. Outcomes Research and Chronic Liver Disease. Transplant Grand Round. Inova Fairfax Hospital. April 2000.
114. How to Assess Evidence? The Evidence Based Approach. 6th World Congress of International Hepatobiliary Association. Washington D.C. June 2004.

Lectures Related to Hepatitis C:

112. A Clinical Overview of Chronic Hepatitis C: The Cleveland Clinic Foundation. Medical Grand Round. Cleveland, Ohio. March 1996.
113. Epidemiology of Hepatitis A, B and C. Hepatitis Foundation International. Cleveland, Ohio. May 1996.
114. Extrahepatic Complications of HCV Infection. The Cleveland Clinic Foundation. Medical Grand Round. Cleveland, Ohio. January 1998.
115. The Challenges of Hepatitis C for Generalists. The Cleveland Clinic Foundation, Department of CME. Cleveland, Ohio. April 1998.
116. Interferon and Ribavirin for Treatment of Chronic Hepatitis C. Cleveland, Ohio. September 1998.
117. Hepatitis C: An update. Akron Gastroenterologists. Akron, Ohio. October 1998.
118. Chronic Hepatitis C: A Review for Primary Care Physicians. Ashtabula County Medical Center. Ashtabula, Ohio. October 1998.
119. Update on Chronic Hepatitis C. 35th Annual Cleveland Clinic Gastroenterology Update. The Cleveland Clinic Foundation. Cleveland, Ohio. November 1998.
120. An Update on Hepatitis C: The Virus and the Disease. Buffalo NY. February 1999.
121. Beyond the 90's: A Healthier Focus for the New Millennium: An Update on Cleveland Hepatitis C. The Cleveland Clinic Foundation. Cleveland, Ohio. April 1999.
122. Treating Hepatitis C: Solutions for A Critical Need. Cleveland, OH. July 1999.
123. Treating Hepatitis C: Solutions for A Critical Need. Farmington, PA. July 1999.
124. Treating Hepatitis C: Solutions for A Critical Need. Hershey, PA. October 1999.
125. Panelist in the State Capitol for Hepatitis C Coalition. Columbus, OH. October 1999.
126. Hepatitis C: A Silent Epidemic. Medical Grand Round. The Cleveland Clinic Foundation. Cleveland, OH. February 2000.
127. Treating Hepatitis C: Solutions for A Critical Need. Cleveland, OH. April 2000.
128. Treating Hepatitis C: Solutions for A Critical Need. Seattle, WA. May 2000.
129. Hepatitis C, Interferon and Depression. Talk for Local Gastroenterologists. Cleveland OH. June 2000.
130. Treating Hepatitis C: Solutions for A Critical Need. Mount Carmel, CA. July 2000.
131. Treating Hepatitis C: Solutions for A Critical Need. Boston, MA. July 2000.
132. Treating Hepatitis C: Solutions for A Critical Need. New York. August 2000.
133. The Impact of Hepatitis C. Inova Fairfax Hospital Medical Grand Round. Fairfax, VA. September 2000.
134. Hepatitis C and Liver Transplantation. Transplant Grand Round. Inova Fairfax Hospital. 2001
135. Hepatitis C: An Update on New Therapies. Medical Grand Rounds. Shady Grove Hospital. January 2001.
136. Hepatitis C: New Therapies. Beachwood Marriott. Beachwood, OH. February 2001
137. An Update in HCV: New Therapies. Tyson's Corner, VA. March 2001.
138. HCV Update. Inova Fairfax Hospital. Trauma Grand Rounds. April 2001.

139. Achieving Optimum Outcomes: Customizing Treatment for Patients with HCV infection. Greenwich, CT. May 5, 2001.
140. American Liver Foundation Support Group. Update on HCV. Oakton, VA. May 6, 2001.
141. American Liver Foundation Support Group. Update on HCV. Woodbridge, VA. May 7, 2001.
142. Northern Virginia/ALF HCV Support Group: An Update on HCV. October 2001.
143. Hepatitis C: An Updated for 2002. Medical Grand Rounds. Inova Fairfax Hospital. December 2002.
144. Extrahepatic Manifestation of HCV. Dermatology Section Meeting. Inova Fairfax Hospital. April 2003.
145. The Role of Adherence on the Efficacy of Antiviral Therapy for HCV. Santa Monica CA. December 2003.
146. The Role of Growth Factors in the Management of Hepatitis C. Chicago IL. March 2004.
147. The Role of Growth Factors in the Management of Hepatitis C. South Beach FL. April 2004.
148. Effective Side Effect Management in Anti-HCV Therapy. New Orleans, LA. May 2004.
149. In Depth Side Effect Management Strategies for HCV Treatment. Miami FL. June 2004.
150. Management of Hepatitis C: 2004 Update. Guest Lecturer. Amgen, Inc. Thousand Oaks, CA.
151. HCV Therapy: Shortfalls in Management. La Jolla, CA. July 2004.
152. Maximizing HCV Therapy. Atlanta, GA. July 2004.
153. Maximizing HCV Therapy: In Depth Side Effect Management Strategies. Boston, MA. July 2004.
154. Maximizing HCV Therapy: Side Effect Management Strategies. Washington DC. July 2004.
155. Management of Hepatitis C Roundtable. Cleveland Clinic. 2004.
156. Helping Patients Stay the Course on Treatment for Hepatitis C. Bethesda, MD. 2004.
157. Striving to Achieve Improved Outcomes: An Integrated Approach to HCV Treatment. Boston, MA. 2004.
158. Anemia Management for Hepatitis C Therapy. Univ. of Michigan Program. Ann Arbor, MI. 2004.
159. Issues in the Management of Adverse Effect of HCV Therapy. Indian Association for Study of Liver Disease, New Delhi, India. 2004.
160. Hepatitis C and its Implications for Rheumatologists. American College of Rheumatology Meeting, Santa Barbara, CA. 2005.
161. An Update on hepatitis C and HIV/HCV Co-infection. Tyson's Corner, VA. 2005
162. Emerging Data in the Management of Hepatitis C. Woodbridge, VA. 2005.
163. Hepatitis C. Scripps Consortium Seminar, Washington D.C. 2005.
164. Hepatitis C Oral Presentations (Co-chair), Digestive Disease Week, Los Angeles CA 2006
165. Managing Hepatitis C. Hot Topic 2007 (CME Program), Norfolk, VA. 2007.
166. Managing Hepatitis C. Hot Topic 2007 (CME Program), Tyson's Corner, VA. 2007
167. Case challenges in HCV: Overcoming Boundaries to Hepatitis C Treatment (CME Program). Miami, Fl. 2007
168. Case challenges in HCV: Overcoming Boundaries to Hepatitis C Treatment (CME Program). Chicago, IL. 2007
169. Case challenges in HCV: Overcoming Boundaries to Hepatitis C Treatment (CME Program). Washington DC. 2007
170. Case challenges in HCV: Overcoming Boundaries to Hepatitis C Treatment (CME Program). New York, New York. 2007
171. Why Is Standard of Care for HCV Treatment Falling Short? American Association for the Study of Liver Disease, Projects in Knowledge CME Program, San Francisco, CA 2008
172. An Update on Chronic Hepatitis C. Second Annual Hepatology Congress. East Palo Alto, CA. December 2008
173. Hepatitis B and Hepatitis C Content Development Meeting. Chronic Liver Disease Foundation, Dallas, TX 2009
174. The Past, Present, and Future of Hepatitis C: A Discussion With the Experts. AGA Institute and Medscape, Chicago 2009

- 175. Hepatitis C and Metabolic Syndrome. CMETV, Chronic Liver Disease Foundation, Chicago 2009
- 176. STAT-C Therapy for Chronic Hepatitis C Round Table (Chair), New York, NY November 2009

Lectures Related to Other Liver Diseases:

- 177. Timing of Liver Transplantation. 32nd Annual Cleveland Clinic Foundation. Gastroenterology Update. Cleveland, Ohio. November 1995.
- 178. Portal Hypertensive Bleeding. 34th Annual Cleveland Clinic GI Update. Cleveland, Ohio. 1997.
- 179. Management of Variceal Bleeding. Metro Health Medical Center. Cleveland, Ohio. Dec 1997.
- 180. First Update from American Association for the Study of Liver Disease. Course Director. Cleveland, Ohio. December 1997.
- 181. Current Concepts in the Management of Acute Variceal Hemorrhage. Teleconference. Cleveland, Ohio. January-March 1998.
- 182. Hepatic Manifestations of Inflammatory Bowel Disease. The Cleveland Clinic IBD Course. 1998.
- 183. Portal Hypertensive Bleeding: The Role of the Endoscopist. 35th Annual Gastroenterology Update. The Cleveland Clinic Foundation. Cleveland, Ohio. November 1998.
- 184. Second Update from American Association for the Study of Liver Disease. Course Director. Cleveland, Ohio. December 1998.
- 185. The Cleveland Clinic Intensive Review of Internal Medicine. Cleveland, OH. June 1999
- 186. An Update on Viral Hepatitis. Ob Gyn Grand Rounds. Cleveland Clinic Foundation. Cleveland, OH. August 1999.
- 187. Ascites. Inova Fairfax Hospital. Housestaff Lecture. January 2001.
- 188. Fulminant Hepatic Failure. Inova Fairfax Hospital. Housestaff Lecture. January 2001.
- 189. Liver Disease in Women. Meet the Professor Session. American Association for the Study of Liver Disease Workshop. Digestive Disease Week. May 2001.
- 190. Associates Course: American Association for the Study of Liver Disease. October 2001.
- 191. Women's Health Issues 2001: Evaluation of Abnormal Liver Enzymes. November 2001.
- 192. Management of Variceal Bleeding: Critical Care Forum. Inova Fairfax Hospital. December 2001
- 193. Viral Hepatitis: University of Michigan. GI/Liver Wrap-Up Course. February 2002.
- 194. Current Treatment and Research Protocols in the Treatment of Hepatitis C: UNOS Region 2 Clinical Forum. Bethesda. March 2002.
- 195. Hepatitis B: To Treat or Not to Treat. ACG/Walter Reed Annual GI Course. Tyson's Corner, VA. March 2003.
- 196. Update on Hepatitis B, Medical Grand Rounds. Inova Fairfax Hospital. July 2003.
- 197. Role of Hematopoietic Growth Factors in Management of Ribavirin-Induced Anemia. Dallas TX. September 2003.
- 198. Epoetin Alfa and Darbepoetin Alfa for Management of Ribavirin-Induced Anemia. Miami, FL. November 2003.
- 199. Hematopoietic Growth Factors for Management of Ribavirin-Induced Anemia. New York, NY. December 2003.
- 200. New Data on Treatment for Hematologic Side Effects. Tarrytown, NY. June 2004.
- 201. Hepatitis B Update for Korean Physician Workshop. Tyson Corner, VA. 2004
- 202. Implication of Hepatitis B. McLean, VA. 2004.
- 203. Management of Hepatic Encephalopathy. Tyson's Corner, VA 2004
- 204. Hepatitis B: Fighting the Invisible Enemy. Seven Corners, VA. 2005.
- 205. Case Presentations by Staff. Visiting Professor, Post Graduate Institutes, Chandigarh, India. 2004.
- 206. Hepatitis B Update. Taiwanese Medical Association, Fairfax, VA. 2005.
- 207. Hepatitis B: Management of Difficult Cases. Fairfax, VA. 2005.
- 208. Integrating Clinical Research into a Business Plan of Hepatology Practice. American Association for the Study of Liver Disease Annual Meeting, San Francisco, CA. 2005.
- 209. Chronic Hepatitis B Treatment. Fairfax, VA. 2005.
- 210. American Liver Foundation's Post-AASLD Review (Chair), Alexandria, VA. 2005.

211. Autoimmune and Metabolic Liver Disease. Hepatology SEP Course. Digestive Disease Week, Washington, D.C. 2007.
212. Research Training Day for Inova Health System: Course Director December 2007
213. Hepatitis B Update. Middlesex Hospital Symposium. Middletown, Connecticut, May 2008
214. Hepatic Encephalopathy CME Meeting. Chronic Liver Disease Foundation Dallas 2009
215. Management of Overt Hepatic Encephalopathy CME Teleconference, Chronic Liver Disease Foundation 2009.
216. Hepatic Encephalopathy Content Development Meeting. Chronic Liver Disease Foundation, Chicago, IL 2009.
217. Non-alcoholic Fatty Liver Disease. Scripps Clinic's 25th Annual New Treatments in Chronic Liver Disease. La Jolla, CA 2010
218. Is Insulin Resistance the Only Treatment Target for Non-alcoholic Fatty Liver Disease? Scripps Clinic's 25th Annual New Treatments in Chronic Liver Disease. La Jolla, CA 2010
219. Update on the Management of Hepatic Encephalopathy. CLDF CME Program. New Orleans, LA 2010
220. Hepatocellular Carcinoma. CLDF CME Program. New Orleans, LA 2010
221. Management of Nonresponders to Previous HCV Therapy: What Lessons Have We Learned? Medscape-AGA CME Program. New Orleans, LA 2010
222. NASH: Noninvasive Markers – Emerging Alternatives to Biopsy: Measuring Steatosis, Fibrosis and Cell Death; What is New and Hot in Clinical Hepatology. Digestive Disease Week, New Orleans, 2010
223. 2010 National Hepatitis B and C Training Program and Treatment Update. Crystal City, VA 2010
224. The Clinical Implications of Managing Cirrhotics. Chronic Liver Disease Foundation, Tysons Corner, VA 2010
225. The Clinical Implications of Managing Cirrhotics. Chronic Liver Disease Foundation, McLean VA 2010
226. Hepatic Encephalopathy Teleweb Presentation. Chronic Liver Disease Foundation 2010
227. Non-Alcoholic Fatty Liver Disease: When should I biopsy? How should I treat? Post Graduate Course. American College of Gastroenterology. San Antonio, Texas, 2010
228. Non-alcoholic Fatty Liver Disease: Non-invasive Fibrosis Biomarkers and Treatment Strategies. State of the Art Lecture, “The 3rd Hepatology and Gastroenterology Post Graduate Course and the 12th International Workshop on Therapeutic Endoscopy”, Cairo, Egypt, December 2010
229. Long Term Mortality, Morbidity and Hepatocellular Carcinoma in patients with NASH and Related Cirrhosis. State of the Art Lecture, “The 3rd Hepatology and Gastroenterology Post Graduate Course and the 12th International Workshop on Therapeutic Endoscopy”, Cairo, Egypt, December 2010
230. Treatment of metabolic syndrome and liver fibrosis. The Fourth Scientific Meeting on Liver Fibrosis, May, 2011, Bordeaux, France.